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Referat: 
Background: Human African Trypanosomiasis (HAT) also called sleeping sickness is an 
infectious disease of humans caused by an extracellular protozoan parasite. The disease, if left 
untreated, results in 100% mortality. However, the available drugs are full of severe 
drawbacks and fail to escape the fast development of trypanosoma resistance. Due to the 
probable similarities in cell metabolism among tumor and trypanosoma cells, some of the 
current registered drugs against HAT were derived from cancer chemotherapeutic research. 
Here too, for the first time, we have demonstrated that the simple ester, ethyl pyruvate, 
comprises such properties. On the other hand initial studies have confirmed the efficacy of 
protease inhibitors in treatment of Trypanosoma cruzi, Plasmodium falciparum and 
Leishmania major. However, studies on efficacy and specific proteases inhibition using HIV-
1 protease inhibitors on T. brucei cells remain untouched. 
 
Methodology/Principal findings: The current study covers efficacy and corresponding target 
evaluation of ethyl pyruvate and HIV-1 protease inhibitors (ritonavir and saquinavir) on T. 
brucei cell lines using a combination of biochemical techniques including cell proliferation 
assays, enzyme kinetics, zymography, phase contrast microscopic video imaging and ex vivo 
drug toxicity tests. We have shown that ethyl pyruvate effectively kills trypanosomes most 
probably by net ATP depletion through inhibition of pyruvate kinase (Ki=3.0±0.29 mM). The 
potential of this compound as an anti-trypanosomal drug is also strengthened by its fast acting 
property, killing cells within three hours post exposure. This was demonstrated using video 
imaging of live cells as well as concentration and time dependency experiments. Most 
importantly, this drug produced minimal side effects in human erythrocytes and is known to 
easily cross the blood-brain-barrier (BBB) which makes it a promising candidate for effective 
treatment of the two clinical stages of sleeping sickness. Trypanosome drug resistance tests 
indicate irreversible killing of cells and a low chance of drug resistance development under 
applied experimental conditions. In addition to ethyl pyruvate our experimental study on 
HIV-1 protease inhibitors showed that both ritonavir (RTV) (IC50=12.23 µM) and saquinavir 
(SQV) (IC50=11.49 µM) effectively inhibited T. brucei cells proliferation. The major 
proteases identified in these cells were the cysteine- (~29kDa Mr) and metallo- (~66kDa Mr) 
proteases. Their proteolytic activity was, however, not hampered by either of these two 
protease inhibitors. 
 
Conclusion/Significance: Our results present ethyl pyruvate as a safe and fast acting drug. 
Hence, because of its predefined property to easily cross the BBB, it can probably be a new 
candidate agent to treat the heamolymphatic as well as neurological stages of sleeping 
sickness. Similarly, HIV-1 protease inhibitors, SQV and RTV, exhibited their 
antitrypanosomal potential but require further anlysis to identify their specific targets. 
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1. Introduction 
 
1.1. Disease background 
 
Prior to the identification of the etiologic agents (Tobey 1906), the disease Human African 
trypanosomiasis (HAT) has long been recognized in West Africa since 1792. In early 1800‘s 
the primary endemic focus areas were observed at the mouth of Congo River. A century later 
these endemic regions extended from mouth of Congo River to Lake Tanganyika indicating 
the association of the disease transmission with water environment. Then it was David Bruce 
who first had shown trypanosomes were spread between animals by the bite of tsetse flies in 
South Africa in 1895 (Lyons 1992). In 1902 Everett Dutton from the Liverpool School of 
Tropical Medicine, identified Trypanosoma gambienseas as the causal agent of sleeping 
sickness in Gambia. Similarly, in East Africa in 1903 Sir Aldo Castellani also isolated 
trypanosomes from patients in Busoga, Uganda, and named the organism Trypanosoma 
ugandense (Castellani 2003; Castellani 1903). Through its continuous journey of spread, the 
disease resulted in death of 500,000 people in Congo within ten years period (1896 to 1906). 
In 1908 it then expanded to Uganda (in Busoga area near to lake Victoria) resulting in the 
death of additional 300, 000 people affecting more than 30% of the population (Gray 1984). 
Recently, WHO reinforced disease control programs and the number of notified cases since 
2000 has shown to steadily decline reaching lower than 10,000 new cases after 2009 (Franco 
et al. 2014). Although 7216 cases were reported in 2012, the estimated number of new cases 
approximate to 20,000 (WHO 2013). 
 
1.2. Epidemiological distribution and disease transmission dynamics 
 
HAT is a highly lethal neglected tropical disease (NTD) caused by an extracellular protozoan 
parasite. The blood stream, lymphatics and central nervous system are its known predilection 
sites within the human host. Epidemiologically, the disease is endemic in 36 sub-Sahara 
African countries and puts more than 60 million people at risk of infection (WHO 1998). The 
current status of disease distribution in Africa involves nearly 30 countries to be affected by 
the disease (WHO 2013). It mainly affects people living in the ―tsetse belt,‖ that 
geographically extends across the continent from Senegal in the West to Somalia in the East 
(Annex 1). This area is the ecological habitat for more than 20 species of the transmitting  
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vector called ‗tsetse‘ flies, which are members of the biting fly of the genus Glossina. 
Currently, most of the HAT infections and the highest risk of contracting the disease occur 
primarily in the Democratic Republic of Congo representing 70% of infections. Chad, South 
Sudan Angola and Central African Republic represent nearly 25% of the remaining cases 
(Franco et al. 2014). 
 
Figure 1. The Atlas of human African trypanosomiasis: progress status (2000-2009). 
(Source: WHO 2013) 
 
The disease causing organism Trypanosoma brucei (T. brucei) is a slender single celled 
flagellated protozoan parasite with a size ranging from 15-35 µm (Smith et al. 1998; 
Matthews 2005). The parasite has three major morphologically identical subspecies causing 
human and animal diseases (Hoare 1972). The subspecies T. brucei gambiense (T. b. 
gambiense) causes the West African form of the disease also called Gambian HAT. On the 
other hand T. brucei rhodesiense (T. b. rhodesiense) causes HAT in East Africa (also known 
as Rhodesian HAT). The third subspecies T. brucei brucei (T. b. brucei), however, infects 
only animals but not humans (Smith et al. 1998). 
 
These three forms of the disease also show variable disease transmission cycles. In the 
Gambians form of the disease the major mechanism of transmission is known to be the 
human-fly-human transmission cycle. This cycle mainly involves Glossina palpalis palpalis,  
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Glossina palpalis gambiensis, Glossina fuscipes fuscipes and Glossina tachinoides. Humans 
are important reservoir hosts because they may carry the parasites within their blood for 
several months without overt clinical symptoms. Transmission of this form of the disease also 
depends on the intensity and frequency of contact between the vector and the host as well as 
the transmission sites that mainly occur in savannah areas, forests, forest galleries and 
mangrove swamps (WHO 1998). 
 
In the Rhodensian disease endemic situations wild animal-fly-human transmission is typical. 
The endemic form of this disease has a sporadic nature with a patchy distribution. Human 
infections are acquired from savanna species of Glossina, principally G. morsitans morsitans, 
G. morsitans centralis, G. swynnertoni, G. pallidipes and G. fuscipes fuscipes. All of these 
disease transmitting vectors are known to preferentially feed on a wide range of wild and 
domestic animals (WHO 1998). 
 
1.3. Biology and life cycle of the trypanosomatidea 
 
Trypanosomes have complex life cycle. During transmission they must adapt either to the 
mammalian bloodstream or to different compartments within the tsetse fly (Matthews 2005; 
MacGregor and Matthews 2010). Within the bloodstream of the mammalian host T. brucei 
species undergo pleomorphism ranging from actively dividing long, slender trypomastigotes 
with a long free flagellum to nondividing short, stumpy forms without a free flagellum 
(Figure 2) (Fenn and Matthews 2007). The single mitochondrion in the long, slender blood 
stream forms (BSF) is reduced with almost no cristae. They also lack cytochromes and the 
Kreb‘s cycle is nonfunctional. Transformation from the long, slender form to the stumpy form 
is marked by a swelling of the mitochondrial canal and the development of tubular cristae. At 
the same time the mitochondrion acquires its functionality in cellular metabolism (Matthews 
2005, Menna-Barreto et al 2014).  
 
When the tsetse fly ingests trypanosomes from the blood of the host, the short, stumpy form 
of the parasite will develop to the midgut stage also called procyclic trypomastigotes. This 
form has a well-developed mitochondrion with an extensively branched network of prominent 
plate like cristae (Menna-Barreto et al. 2014). Unlike the BSFs, the procyclic forms possess 
cytochromes. This form, however, utilizes amino acids rather than glucose for energy 
metabolism and produces acetate and succinate instead of pyruvate. The trypanosome then 
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migrates from the midgut to the salivary glands of the fly and finally transforms into a 
metacyclic form, which is the infectious form to the vertebrate host (Opperdoes 1987; 
Matthews 2005). 
 
 
Figure 2. Transmission cycle of Human African Trypanosomiasis (Source: CDC) 
 
1.4. Public health significance 
 
Human trypanosomiasis is a severe constraint to health and development in many parts of the 
sub-Saharan Africa. If left untreated, it causes biological damage and ultimately leads to 
death. If treated late, it leaves major and irreversible consequences. For instance, mental 
disturbances in patients because of the secondary stage of the disease may lead to 
stigmatization; a mother may give birth of a child with physical and intellectual retardation.  
Besides, abortion, sterility and other gynecological problems are also common in infected 
women (Robays et al. 2004). Several members of a family are observed to mutually get 
infected during epidemics and time and money spent in search of a cure might also drain 
family‘s resources. During epidemics, higher mortality, lower birth rate and migration 
resulting in the depopulation of entire areas are the combined effects of the disease at a 
community level. Even when an epidemic regresses, the affected population takes a long time 
to recover and regenerate. Sleeping sickness is, therefore, a real threat to the survival of 
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families in particular and communities in general (WHO 1998; Smith et al. 1998; Kuzoe and 
Schofield 2004). 
 
1.5. Clinical stages and disease progression 
 
Clinically T. b. rhodesiense usually causes an acute form of the disease, whereas T. b. 
gambiense leads the chronic form (Brun et al. 2010). Depending on the existence of T. brucei 
parasites within the central nervous system, the disease can be categorized as stage 1 or stage 
2. In stage 1, parasites proliferate at the site of inoculation by the bite of a fly, which results in 
an inflammatory nodule or ulcer termed as ‗chancre‘ which usually heals within a month with 
overlying desquamation and sometimes with altered pigmentation. This dermal lesion occurs 
in about 50% of all rhodesiense infections but in very rare proportions in gambiense patients. 
Once they get into the skin parasites will be spread to the draining lymph nodes and reach the 
bloodstream, initiating the ―haemolymphatic stage‖ of the disease (Vickerman 1985). This 
stage is characterised by general malaise, headache, and undulating fever. In the acute form of 
the disease, pancarditis with congestive heart failure, pericardial effusion, and pulmonary 
oedema can cause mortalities at the very early stage (Odiit et al. 1997), whereas chronic form 
of the disease shows a more insidious progression frequently misdiagnosed with other febrile 
illnesses. A generalised lymphadenopathy, also called Winterbottom‘s sign, commonly 
occurring in the posterior triangle of the neck which becomes visible after several weeks of 
infection is still used to describe posterior cervical lymphadenopathy and considered as a 
typical sign of chronic form of HAT (Checchi et al. 2008). A circinate rash, pruritus, and 
generalised oedema are also listed under the non- specific features of stage 1 HAT.  
 
In the second stage of the disease, parasites invade internal organs, including the CNS. In T. 
b. rhodesiense invasion of internal organs occur within few weeks post infection but may take 
over several months or even years when infected with T. b. gambiense. Immunosuppression is 
a characteristic in this stage wherein nitric oxide and prostaglandin apparently involved early, 
and cytokines including interleukin-10 also reach amplified concentrations lately in the 
cerebrospinal fluid. Although the portal of entry is proposed to be through the choroid plexus, 
the mechanism and reason of entry into the CNS is not yet defined (Barrett et al. 2003; Brun 
et al. 2010; Kuepfer et al. 2011; Frevert et al. 2012). 
 
 
 
[Netsanet W. (2015). PhD Dissertation] 6 
 
During progression of the second stage of the disease symptoms like sleep disturbance due to 
a disorder in the circadian cycle and severe headache will become clearly observed (Buguet 
1999). The name sleeping sickness was also given because of the observation of diurnal 
somnolence and nocturnal insomnia in some patients without altering the overall sleep time in 
early infections (Kuepfer et al. 2011). Personality changes, impaired mental functions, ataxic 
dyskinesia are observed in most of the patients, Parkinson‘s disease like clinical features 
involving the basal ganglia are also usual and confirmed in clinical case reports using MRI. 
Endocrine abnormalities like impotence can also be seen in most patients. In untreated 
patients progressive weight loss and CNS involvement that ends up with coma and death is a 
typical feature (Barrett et al. 2003). 
 
During diagnosis, even with the support of concentration techniques like double 
centrifugation, trypanosome cells are infrequently detected in the cerebrospinal fluid (CSF). 
Host immune responses are, however, good indicators of the second stage of the disease 
because of the increase in IgM concentration, lymphocyte count (>5x10
6
/L), cerebrospinal 
fluid protein (>25 mg/100 mL) and detection of foamy plasma cells (pathognomonic Mott‘s 
modular cells) (Barrett et al. 2003; Bouteille and Buguet 2012). 
 
1.6. Current challenges of disease control 
 
Over the last century HAT has ruined Africa with severe epidemics. Hope was enlightened to 
bring the disease under control in the 1960s through vector control and establishment of 
mobile teams conducting active surveillance in the population. However, the re-emergence 
and outbreaks of disease were observed since after the mid1970s until the end of the 20
th
 
century due to the interruption of disease control activities because of frequent social 
upheavals, wars and population movements in the continent which were complemented with 
shortage of funds for disease control (Simarro et al. 2008; Tong et al. 2011; WHO 2013). 
 
In disease diagnosis the card agglutination test for trypanosomiasis (CATT) was widely used 
since 1978. Its primary purpose was for screening the population affected by T. b. gambiense, 
but not in T. b. rhodesiense. However, sensitivity and specificity of the test is insufficient to 
confirm a definitive diagnosis. Parasitological tests such as microscopic examination of the 
lymph and blood, must, therefore, be performed to prove the presence of parasites in CATT-
positive individuals. The problem in diagnosis continues because the parasitological tests are 
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also insufﬁciently sensitive, tedious and time taking (Magnus et al. 1978; Camara et al. 2010). 
Once a patient is infection positive, systematic disease stage determination will follow. This 
consists of determination of increase in the number of white blood cells, increase in protein 
concentration and presence of parasites within the cerebrospinal fluid. This protocol requires 
a lumbar puncture which is an invasive and painful procedure commonly unaccepted by 
patients (Lutumba et al. 2005).  
 
A progressive result using ELISAs on saliva to detect T. b. gambiense has come into picture 
with 90% sensitivity and specificity. Unfortunately ELISA is not an applicable technique in 
mass screening because it needs a number of primary antibodies which are not stable at 
ambient temperature. Unlike CATT agglutination tests performed on whole blood or serum, 
ELISAs performed on saliva in T. b. gambiense patients appeared to be more than 90% 
sensitive and speciﬁc for the detection of trypanosome-speciﬁc antibodies in the saliva (Lejon 
et al. 2008; Hasker et al. 2010; Lejon et al. 2010). Overall, there is still no accurate serological 
screening test and no promising laboratory breakthrough to detect T. b. rhodesiense infection 
in the ﬁeld, where similar tests used for T. b. gambiense are less accurate for T. b. rhodesiense 
(Seke and Fawzi 2012). The absence of vaccines because of the inability of patients to 
develop a sterilizing immunity after a natural infection is another discouraging challenge in 
disease control strategies (Chappuis et al. 2004). 
 
Treatment depends only on few parentral drugs namely suramin, pentamidine, melarsoprol 
and eﬂornithine. All these drugs are either unsafe or not fully effective in both forms of the 
disease against both parasite species. Besides the management of patients using either of these 
drugs requires complex administration tools, well trained staff and are difficult and risky to 
apply to patients (Welburn et al. 2009). The newly introduced nifurtimox-eflornithine 
combination therapy (NECT) has given some hope in the treatment of the second stage of the 
gambiense form of the disease. However clinical reports indicated that up to 68% of treated 
patients experienced its adverse effects like vomiting, dizziness, nausea, headaches, 
abdominal pain, joint pains, seizures, and insomnia and convulsions. Like in melarsoprol 
medical personnel also need special training to admisniter eflornithine. Besides the cost per 
single treatment was reached upto €336 in 2010. Parasites are also observed to easily devlop 
resistance against NECT in vitro.These reasons could potentially treated the future of NECT 
in the long term (Vincent et al. 2010; Babokhov et al. 2013; Alirol et al. 2013).  
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Vector control is also the main tool for disease control. It involves insecticide application 
including aerosol spraying (Lee 1969), insecticide-treated targets, traps or animals (pour-ons) 
(Somda et al. 2006; Bauer et al. 2011). Aerosol spraying of insecticides requires substantial 
economic and infrastructural support even though it can effectively clear large areas of tsetse 
ﬂies in a relatively short time. Pour-ons or selective spraying application of insecticides to 
animals is also an effective technique in savannah tsetse control but we lack a similar 
technique in reverine tsetse fly species which are considered to be the major vectors of HAT. 
The relative low cost and simplicity of the insecticide treated traps or targets makes them 
available for use by local communities, but they are applied on a small scale basis in which 
case tsetse fly re-invasion may possibly be a threat (Torr et al. 2011; McCord et al. 2012). 
 
An advanced technique of vector control involves the sterile male insect technique (SIT). 
Basically, the principle of this technique is based on the reproductive nature of the female 
tsetse fly. The female naturally mates with a male just once in her life time and can produce 
eggs throughout the rest of her productive life. The male tsetse, however, can mate with 
thousands of females. Sterilizing one male tsetse indirectly results in sterilization of thousands 
of females. SIT, therefore, involves the release of laboratory-reared and sterilized males to 
compete with wild males so that inseminated females produce no offspring (Baylis and 
Stevenson 1998; Dyck et al. 2005). This method has been effectively used in Unguja Island in 
Zanzibar (Vreysen et al. 2014). For the technique to be effective there should be natural 
barriers like mountains, rivers or the area should be an island to avoid the entrance of or 
invasion with multiple wild tsetse species. The cost of SIT is, however, many million dollar 
project since collection of wild flies, rearing and release of sterile male tsetse flies require a 
big project team, advanced tsetse rearing plants and helicopters, respectively. 
 
Vector‘s longevity, competence to its hosts and its mating capacity can be impaired using the 
genetic or chemotherapeutic manipulation of their gut microbiota. Wigglesworthia, Sodalis 
and Wolbachia, are among the known gut symbionts that can bring the aforementioned 
impacts (Pais et al. 2008; Werren et al. 2008; Weiss et al. 2013; Wang et al. 2013). Turning 
such new knowledge into practice is still a question of interest that needs further research. 
Despite the considerable progress in vector control, an ideal strategy easily accessible and 
applicable to the population at risk does not yet exist. 
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1.7. Current drugs and their clinical applications  
 
As is mentined earlier, since there is no vaccine for disease control, drugs are the only 
therapeutic options for treatment of HAT. However, the current drugs in use are old, scarce, 
highly toxic, and encounter parasite resistance. They are also given depending on the stage of 
the disease. For instance, three of the available drugs were developed > 50 years ago. 
Suramin, a polyanionic sulfated naphthylamine introduced since 1922, and pentamidine, an 
aromatic diamidine (Figure 3 and Table 1) first used in 1937, are effective against the early 
stages of T. b. rhodesiense and T. b. gambiense infections, respectively. Suramin has multiple 
targets. It acts by interfering with enzymes of the glycolytic pathway and is known to 
concentrate in the parasite through receptor mediated endocytocis. The drug has three 
negatively charged groups at each end of the molecule that interact with positively charged 
surface antigens of the glycolytic enzymes (WHO 1998; Barrett and Barrett 2000). The 
typical therapeutic protocol using suramin starts with 5 mg/kg at day 1 and continues using 10 
mg/kg at day 3, then 20 mg/kg at days 5, 11, 23, and 30, given by slow intravenous injections. 
The drug resulted in a range of side effects such as nausea, vomiting, fatigue, anaphylactic 
shocks, severe cutaneous reactions, neurotoxic signs like headache and peripheral neuropathy, 
and cases of renal failure (Jacobs et al. 2011). 
 
Figure 3. Chemical structure of the currently available drugs against sleeping sickness (Source: Steverding 
2010). 
 
Pentamidine is usually well tolerated, with hypotension and hypoglycaemia as the most 
common reported side-effects (Legros et al. 2002). Its entry into the cells is energy dependent  
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with the support of adenine/adenosine P2 transporter in combination with a low capacity 
high- affinity (HAPT) and a high capacity low affinity transporters (LAPT). This might be the 
good reason why parasites are unable to easily develop resistance against the drug (Sands et 
al. 1985; Jacobs et al. 2011). Even though the molecular mode of action of pentamidine is not 
well defined early work indicated that a lowering of blood glucose level is essential for its 
trypanocidal action. It is also known to bind to parasite DNA, accumulates in lysosomes and 
inhibits plasma membrane Ca
++
 ATPase (WHO 1998). The present recommended regimen is 
7-10 doses of 4 mg/kg/day given intramuscularly once daily or every other day for 7 days. 
Pentamidine causes significant toxicity in 50% of the patients, with life threatening 
hypoglycemia being the most serious (Denise and Barrett 2001; Steverding 2010; Jacobs et al. 
2011). 
 
Table 1. Summary of current drugs used to treat human sleeping sickness trypanosoma in  
              Human Africantrypanosomiasis. 
 
 
 
For the late stage of the disease melarsoprol, eflornithine, and nifurtimox (Fig. 3 and Table 1) 
are given according to the parasite species and drug resistance pattern. Melarsoprol is an 
organo-arsenical compound that has been in use since 1949 for both forms of HAT 
(Friedheim 1949). It inhibits trypanothion reductase by forming a stable complex with its 
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substrate called trypanothione, a low molecular weight dithiol and an antioxidant functionally 
analogues to the mammalian gluthation (Spinks et al. 2009). There are indications that 
melarsoprol also interfers energy metabolism by inhibiting glycolysis (WHO 1998). The most 
common treatment protocol consists of three to four series of therapies separated by rest 
periods of 7-10 days. In each series, patients are given one intravenous injection per day for 3-
4 days. Alternatively it has recently been proposed to treat T. b. gambiense based on 
pharmacokinetic investigations. This consists of ten consecutive injections of 2.2 mg/kg per 
day and the preliminary results bring a non-significant proportion of adverse skin reactions 
without reduction in efficacy when compared with the standard protocol. When melarson 
oxide is combined with dimercaprol it gives the drug melarsoprol (MelB). Dimeracprol also 
called British Anti-Lewisite (BAL) is an antidote to arsenic poisoning which was developed 
and used during World War II. In 5–10% of patients the drug results reactive encephalopathy 
with a case fatality rate of upto 50% (Denise and Barrett 2001). It has also been reported that 
there is a high therapeutic failure and the P2 transporter has been incriminated for the parasite 
resistance to the drug. At times when eflornithine is not available, melarsoprol is 
recommended to treat T. b. gambiense similar to that in late stage T. b. rhodesiense (Jacobs et 
al. 2011). 
 
Eflornithine (DL-alpha-difluoromethylornithin) (Fig. 3) inhibits the polyamine biosynthesis 
by targeting the ornithine decarboxylase (ODC) (E.C.4.1.1.17) (Table 1) which is the first 
enzyme involved in this process. The drug is the only newly registered molecule since 1980 
applied successfully to treat the second stage T. b. gambiense and despite its lower efficacy it 
can also be used for T. b. rhodesiense (Oredsson et al. 1980; Barrett et al. 2007). The ODC 
enzyme activity in T. b. rhodesiense is higher than in T. b. gambiense and the half life (t1/2) of 
the enzyme in the respective parasite species is 4.3 hrs and 18-19 hrs which makes the 
rhodesiense spp. to be more resistant than their gambiense counter species (Iten et al. 1997). 
This drug is better tolerated than MelB but is still difficult to administer because patients need 
to be given 400 mg/kg/day in four daily i.v. infusions for 7 or 14 days. It may also result 
pancytopenia, diarrhoea, convulsions, and hallucinations but all these adverse effects can be 
reversed if treatment is discontinued. Oral formulation of eflornithine is in clinical 
investigations by WHO‘s special programme for research and training in tropical diseases 
(WHO/TDR). If fully successful the oral administration is preferable in resource poor settings 
even though the current results showed higher relapse rate and frequency of diarhoea when 
compared with the i.v. infusion formula (WHO 1998). 
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Nifurtimox, marketed as Lampit, is another cheap, orally administered drug which was first 
used to treat American trypanosomiasis (Trypanosoma cruzi) (Fig. 3 and Table 1) and 
resulted in a 50-80% cure rate in monotherapies against T. b. gambiense (Janssens and 
Muynck 1977; Docampo et al. 1981; Pepin et al. 1989; Smith et al. 1998). And recently a 
clinical trial of nifurtimox-eflornthine combination therapy (NECT) using a shortened course 
of eflornithine has been completed (Priotto et al. 2006; Priotto et al. 2009; Alirol et al. 2013) 
The cure rate for NECT (96.5%) was higher than for eflornithine given alone (91.6%). NECT 
is safer than eflornithine alone because it results fewer sever adverse effects (14% vs 29%) 
and lower treatment related deaths (0.7% vs 2%) both of which are actually lower than the 
treatment related deaths in melarsoprol (5.9%). The mechanism of action of nifurtimox is, 
however, not yet known. It might be that free radicals generated during the reduction of the 
single electron in the nitro group of nifurtimox which cause a toxic effect on the proteins 
and/or DNA of trypanosomes (WHO 1998). Therefore, NECT was observed to be more 
effective probably because of the synergistic effect of these two compounds as nifurtimox 
induces oxidative stress and eflornithine reduces the trypanothione level which is the key 
metabolite used in protecting against oxidative stress (Docampo et al. 1981). During NECT 
therapy toxicity seems to increase with dose and duration of treatment (Barrett et al. 2007). In 
nifurtimox alone anorexia and toxic effects to the central and peripheral nervous systems have 
also been observed (Castro et al. 2006).  
 
In conclusion, the treatment of HAT is hampered by the limited number and the toxicity of 
trypanocidal drugs and their difficult administration, as well as by the increasing number of 
treatment failures. Even the current drugs under clinical trial are coming with all their draw 
backs because of lack of options to discover a safe and effective compound that can act 
against both parasite species in both stages of the disease. This situation calls for more 
research and development of promising compounds to ensure new drug availability in the 
longer term. T. brucei has a number of novel metabolic pathways and unusual biological 
features that are understudy for their potential in drug discovery programs.  
 
1.8. Targets for drug discovery 
 
1.8.1. Energy metabolism 
For its supply of ATP the blood stream form (BSF) T. brucei is solely dependent on 
glycolysis because it lacks functional oxidative phosphorylation. The enzymes involved in the 
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conversion of glucose to glycerol and glycerate-3-phosphate are enclosed in microbodies 
called glycosomes, whereas phosphoglycerate mutase, enolase and pyruvate kinase are 
located within the cytosol of the cells (Fig. 4) (Fairlamb et al. 1986; Schaftingen et al. 1987). 
All of the enzymes in the glycolytic pathway have been described, isolated and purified, 
either through classical or recombinant means, allowing a comprehensive understanding of 
the kinetics and flux of the pathway. As such, enzymes in this pathway are attractive targets 
for trypanocidal drugs (Verlinde et al. 2001; Lakhdar-Ghazal et al. 2002; Albert et al. 2005; 
Hornberg et al. 2007; Coley et al. 2011). Since much of the details on the pathway have been 
reviewed, only significant concepts or findings to understand the attractiveness of glycolytic 
enzymes as drug targets will be covered here. 
 
 
 
Figure 4. The Glycolytic Cycle. Schematic representation of glycosomal and mitochondrial 
metabolism of bloodstream-form (A) and procyclic-form (B) Trypanosoma brucei. (Source: Lopez et al. 2012) 
Excreted end-products from glucose metabolism are in black characters on a grey rectangle as background. 
Dashed arrows indicate steps which have not been shown to significantly occur, or which are supposed to occur 
at a background level or not at all, under standard growth conditions (glucose-rich medium). Abbreviations: 
1,3BPGA, 1,3-bisphosphoglycerate; c, cytochrome c; DHAP, dihydroxyacetone phosphate; e−, electrons; F6P, 
fructose 6-phosphate; FBP, fructose 1,6-bisphosphate; FUM, fumarate; GAP, glyceraldehyde 3-phosphate; G6P, 
glucose 6-phosphate; MAL, malate; OAA, oxaloacetate; PEP, phosphoenolpyruvate; 2PGA, 2-
phosphoglycerate; 3PGA, 3-phosphoglycerate; PYR, pyruvate; SCoA, succinyl-CoA; SUC, succinate. Enzymes 
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are: 1, hexokinase (HXK); 2, 6-phosphoglucose isomerase; 3, phosphofructokinase (PFK); 4, fructose-1,6-
bisphosphatase (FBPase); 5, aldolase; 6, triosephosphate isomerase; 7, glycerol-3-phosphate dehydrogenase 
(G3PDH); 8, glycerol kinase (GK); 9, glyceraldehyde-3-phosphate dehydrogenase (GAPDH); 10a, glycosomal 
phosphoglycerate kinase; 10b, cytosolic phosphoglycerate kinase; 11, phosphoglycerate mutase; 12, enolase; 13, 
pyruvate kinase (PYK); 14, pyruvate phosphate dikinase (PPDK); 15, phosphoenolpyruvate carboxykinase 
(PEPCK); 16, glycosomal malate dehydrogenase; 17a, cytosolic fumarase; 17b, mitochondrial fumarase; 18a, 
glycosomal NADH-dependent fumarate reductase (NADH-FRD); 17b, mitochondrial NADH-dependent 
fumarate reductase (NADH-FRD); 19a, cytosolic malic enzyme; 19b, mitochondrial malic enzyme; 20, pyruvate 
dehydrogenase complex (PDH); 21, unknown enzyme; 22, acetate:succinate CoA-transferase; 23, succinyl-CoA 
synthetase; 24, rotenone-sensitive NADH dehydrogenase (complex I of the respiratory chain); 25, rotenone-
insensitive NADH dehydrogenase; 26, FAD-dependent glycerol-3-phosphate dehydrogenase; 27, succinate 
dehydrogenase (complex II of the respiratory chain); 28, ubiquinone; 29, SHAM-sensitive alternative oxidase; 
30, complex III of the respiratory chain; 31, complex IV of the respiratory chain; 32, F0F1-ATP synthase. 
 
1.8.1.1. Hexokinase  
 
Similar to the mammalian cells the trypanosoma brucei hexokinases (HKs) are also the 
glycolysis pathway starting enzymes catalyzing the phosphorylation of glucose from ATP to 
form glucose-6-phosphate (G6P). The T. brucei genome contains two nearly identical (with 
98% similarity) hexokinase isozymes (HK1 and HK2) that differ primarily in the C-terminus. 
This difference appears to be important in regulation of hexokinase activity through 
heterooligomer formation between HK1 and HK2. Studies showed recombinant HK1 has HK 
activity but not recombinant HK2 (Morris et al. 2006). Unlike other eukaryotes T. brucei HK1 
will not be regulated by ADP and G6P. However, myrstate, a critical fatty acid in T. brucei, 
can inhibit this enzyme. Myristate get regulative nature, apparently through modulation of 
oligomer formation among these two isozymes (Chambers et al. 2008b). Hexokinase was 
shown essential by RNAi (Chambers et al. 2008b) and an inhibitor of T. brucei HK1, 
lonidamine is shown to be trypanocidal (Chambers et al. 2008a). 
 
1.8.1.2. Phosphoglucose isomerase and Phosphofructokinase 
 
Both enzymes have been expressed and their X-ray structures have been determined (Abell et 
al. 1995; Arsenieva et al. 2009; McNae et al. 2009). Relative to other protozoal, bacterial and 
mammalian orthologs the crystal structures of T. brucei PFK reveal its unique features. The 
active site of T. brucei PFK is a chimera of the ATP-bound form of the tetrameric PFK and 
ATP-dependent PFK. This active site contains amino acid residues and structural features 
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characteristic of both types of PFK. This structure and mechanismic peculiarities of T. brucei 
PFK compared with bacterial and mammalian PFKs provide opportunities for design of T. 
brucei spp specific inhibitors. Hence the synthesis and evaluation of a series of T. brucei PFK 
specific inhibitors like 2,5-anhydro-D-mannitol derivatives has been described (Nowicki et al. 
2008). Similarly, inhibitors like suramin, agaricic acid, and 5-phosphoarabinonhydroxamic 
acid were observed to efficiently inhibit the T. brucei phosphoglocose isomerase (Arsenieva 
et al. 2009). 
 
1.8.1.3. Fructose-1,6-Bisphosphate aldolase 
 
The reversible aldol cleavage of fructose 1, 6-bisphosphate to dihydroxyacetone phosphate 
(DHAP) and D-glyceraldehyde-3-phosphate (D-GA3P) is catalyzed by the aldolase enzyme 
which has long been the target of a structure-based drug design (Chudzik et al. 2000). 
Relatively T. brucei enzyme selective inhibitors, when compared with the orthologous 
enzymes in the rabbit muscle, were based on the 1,6-dihydroxy-2-naphthaldehyde and 2,5- 
dihydroxybenzaldehyde scaffolds (Dax et al. 2006). However, these phosphyorylated 
inhibitors were not effective against T. brucei, probably because of their poor membrane 
permeability. This issue was revealed by preparation of phosphate ester prodrugs that finally 
showed better activity in a whole cell assay (Azéma et al. 2006). 
 
1.8.1.4. Phosphglycerate Kinase 
 
This enzyme converts 1,3-bisphosphoglycerate to 3-phosphoglycerate and is relatively less 
characterized than other enzymes within the glycolytic pathway. However, it has been 
reported that the adenosine analogue tubercidin inhibits T. brucei phosphoglycerate kinase 
and exhibits a trypanocidal activity (Majumder et al. 2011). 
 
1.8.1.5. Pyruvate kinase 
 
Mammals possess four isoenzymes of pyruvate kinase: M1 mostly in skeletal muscle, M2 in 
many tissues, L in the liver, and R in red blood cells. The sequences of T. brucei pyruvate 
kinase display 47–51% identity to the various human isoenzymes. As to in other mammalian 
cells T. brucei pyruvate kinase catalyzes the phospho-transferring from phosphoenolpyruvate 
to ADP to produce ATP and pyruvate which is the last reaction in the glycolytic cycle. Since 
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there is no net synthesis of ATP or reduction of NAD+ occurring within the glycosome, these 
compounds are kept in equilibrium within these organels and there is no requirement of net 
transport of these compounds from and to the glycosome. This indirectly means in 
trypanosomes the net ATP is generated by the cytosolic pyruvate kinase (Visser and 
Opperdoes 1980). Mammalian pyruvate kinases differ in their activity regulation from the 
trypanosomatid enzyme. The M1 isoenzyme does not exhibit allosteric properties, while a 
different effector, namely fructose 1,6-bisphosphate, regulates the three other isoenzymes. In 
trypanosomatids, fructose 2,6-bisphosphate is an effector that allosterically regulates the 
enzyme by promoting its active R state (Verlinde et al. 2001). The unique allosteric features 
of the trypanosomatid effector site become apparent from structural studies on yeast and E. 
coli. A study done by Nowicki, et al also confirmed pyruvate kinase inhibitors such as 
furanose sugar amino amides as promising antitrypanosomal drug candidates (Nowicki et al. 
2008). This evidence has been strengthened in that the trivalent arsenicals like the 
trypanocidal drug melarsoprol are thought to cause cell death by inhibition of glycolysis at the 
level of pyruvate kinase (Flynn and Bowman 1974). 
 
1.8.1.6. Pyruvate transporter 
 
In the blood stream forms of T. brucei, pyruvate is the final product of the glycolytic cycle 
and its export is an essential physiological process. Blockage of the pyruvate transporter is 
speculated to result in the accumulation of the endogenous pyruvate into toxic levels of 
intracellular acidification and osmotic distabilisation which might lead to cell death. This was 
revealed by the lethal effect of inhibition of the T. brucei pyruvate transporter gene expression 
by RNAi using a gene encoded in saccharomyces cervisea (Sanchez 2013).  
 
Therefore, it can be concluded that in Trypanosomatidae the glycolysis cycle offers plenty of 
opportunities to develop a new drug candidate because of the aforementioned reasons 
including the peculiar organization of the pathway in these parasites, and the occurrence of 
unique features in the structure and/or mechanism of many of the enzymes involved within 
this metabolic process. According to all the various research activities  it is clear that 
considerable progress has already been made toward the development of such drugs (Verlinde 
et al. 2001).  
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1.8.2. Proteolysis 
 
Many studies and reviews are done on the biological function, classification, and 
chemotherapeutic role of proteases in different life forms including cancer, viral pathogens  
and parasites (Nkemngu et al. 2002; Caffrey et al. 2002; Rosenthal 2004; Shen and Chou 
2009; Mott et al. 2010; Blaauwen et al. 2014). Hence it is known that proteases are ubiquitous 
in all forms of life and catalyze the enzymatic degradation of proteins.  
 
In trypananosomatids the study of proteases attracted considerable attention because these 
enzymes are known to get involved in various activities including modulation of the host 
immune system, invasion and destruction of host cells or tissues as well as parasite migration. 
They also support cell growth, development and proliferation by taking part in the acquisition 
of essential nutrients for survival. Besides, they are considered to be parasite virulence factors 
(Vermelho et al. 2010; Steverding et al. 2012). Therefore, they are also promising targets for 
the design of antimicrobials against trypanosomatid diseases (Troeberg et al. 1999; Fujii et al. 
2005; Vermelho et al. 2010). 
 
While serine proteases dominate in mammals, parasitic organisms like trypanosomatids 
commonly rely on cysteine proteases throughout their lifecycle (Kerr et al. 2010). In T. brucei 
cells, two forms of cysteine protease, cathepsin B-like and cathepsin L-like subfamilies of the 
papain family, enzyme are present. The enzymes in T. b. brucei and T. b. rhodesiense are 
termed as trypanopain-Tb (or brucipain) and rhodesain, respectively (Vermelho et al. 2010; 
Geiger et al. 2011). In vitro and in vivo RNAi studies have shown that T. brucei cathepsin B is 
essential for the growth, but not brucipain. Data suggests that TbCatB plays a role in 
degradation of host transferrin for iron acquisition (Ehmke et al. 2012). Brucipain on the other 
hand, localized in lysosomes of blood stream forms of T. brucei (Steverding and Tyler 2005) 
has been shown to form active complexes with kininogen, and these circulating complexes 
may confer some advantage to the parasite by modulating host physiology or the immune 
response. It was also demonstrated that this enzyme plays an important role in the 
bloodstream forms of T. b. gambiense during transendothelial migration through the human 
blood-brain barrier, which is correlated to the ability to evoke calcium fluxes in brain 
microvascular endothelial cells (BMECs) (Vermelho et al. 2010). Besides to their functional 
essentiality, the relative structural variability of cysteine proteases in parasites compared to 
their mammalian hosts makes them attractive targets for the development of new antiparasitic 
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chemotherapy (McKerrow et al. 1999; Sajid and McKerrow 2002; Klemba and Goldberg 
2002; Castro et al. 2011).  
 
Other than the cysteine peptidases, T. brucei has three classes of metallopeptidase or Major 
Surface Protease (MSP) genes, called MSP-A, -B and -C, that are differentially expressed 
during the parasite life cycle. In addition, MSP-B protein is a surface-located metallopeptidase 
that plays a role in the release of the variant surface glycoprotein (VSG) during differentiation 
from bloodstream form to procyclic form (the insect form) trypanosomes. These infectious 
agents also contain a serine oligopeptidase, oligopeptidase B, which is implicated in the 
anomalous degradation of host peptide hormones. T. brucei serine proteases like Prolyl Oligo 
Peptidases also mediate collagenolytic activity hydrolyzing purified type I human collagen 
and mesenteric stretched collagen fibers. This could contribute to parasite spreading in the 
host by facilitating its penetration through the endothelium of blood and lymphatic vessels 
contributing to the disruption of the BBB by the cysteine proteases (Bastos and Izabela et al. 
2010). These enzymes have, in fact, been identified as a target of several trypanocidal drugs, 
such as suramin (Morty et al. 2005; Grandgenett et al. 2007; Vermelho et al. 2010). The 
aspartic peptidases of Trypanosomatidae on the other hand belong to two clans (one or more 
peptidase families evolutionarily arisen from a single origin) called clans AA and AD. Clan 
AA consists of the classical aspartic peptidases and clan AD comprises those that hydrolyze 
peptide bonds within the biological membranes. Until recently, the products of aspartic 
peptidase genes in trypanosomatids were poorly or only indirectly characterized (Santos et al. 
2013). 
 
Eventhough not well studied like cysteine proteases, inhibition of the metallo-, serine 
oligopeptidase and aspartic proteases have similar roles in development of chemotherapeutics 
in trypanosomatids (Troeberg et al. 1999; LaCount et al. 2003; Steverding and Tyler 2005; 
Santos et al. 2013). 
 
1.9. Ethyl pyruvate 
 
The endogenous pyruvate is an effective scavenger of reactive oxygen species (ROS) (Song et 
al. 2004) which makes it capable of restraining inflammatory responses within the host. 
However, the clinical use of pyruvate is hampered by its instability and toxicity (Sharma, 
Mongan 2010). The toxicity may probably come because the aqueous solutions of pyruvate 
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undergo a spontaneous aldol-like condensation reaction to form parapyruvate, which interfere 
with the tricarboxylic acid cycle, inhibiting mitochondrial respiration (Kao and Fink 2010). 
To solve this problem, producing a more stable compound that prevents the adverse effects of 
pyruvate while providing similar anti-inflammatory benefits has become a necessity. Because 
of which, ethyl pyruvate, a stable lipophilic pyruvate derivative, was developed and first  
evaluated by (Fink 2001) as an option to using pyruvate. Currently, ethyl pyruvate is 
classified as GRAS (generally regarded as safe) by the Food and Drug Administration, and it 
has already been used in clinical trials (Bennett-Guerrero et al. 2009; Schroeder et al. 2011). 
In vivo, ethyl pyruvate provides anti-inflammatory benefits in experimental models of septic 
shock, polymicrobial sepsis, acute pancreatitis, alcohol hepatitis, acute lung injury, burn, 
radiation damage, myocardial, and mesenteric or hepatic ischemia/reperfusion, extrahepatic 
biliary obstruction, zymosan-induced multiple organ failure, and hemorrhage (Ulloa et al. 
2002; Fink 2005; Fink 2008; Cai et al. 2009; Dong et al. 2010; Crawford et al. 2011). Ethyl 
pyruvate‘s mechanism of action as an anti-inflammatory agent is not completely understood. 
In this regard glutathione depletion has primarily been thought to be its mechanism of action 
(Song et al. 2004). Other studies added that it decreases expression of proinflammatory 
cytokines including TNFa, IL-1b and IL-6 by inhibiting the binding of NF-kB to nuclear 
DNA (Tawadrous et al. 2002; Ulloa et al. 2002; Yang et al. 2002; Li et al. 2009). It is also an 
antioxidant and reactive oxygen species scavenger (Tawadrous et al. 2002; Karabeyoğlu et al. 
2008; Schroeder et al. 2011). 
Table 2. The background relationships of anti-trypanosome drugs and anti-cancer agents. 
 
 
                                            (Sources: Meyskens and Gerner 1999; Steverding 2010; WHO 2013) 
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In trypanosomes it has been observed that all the available registered drugs against HAT are 
derived from cancer therapeutic research (Table 2) (Meyskens and Gerner 1999; Barrett and 
Barrett 2000). This relationship of antitrypanosomal and anticancer drugs encouraged us to 
test similar other compounds with anti-cancer properties. In this regard, we have recently 
shown that ethyl pyruvate exhibits its anti-cancer property by inhibiting glyoxalases 
[glyoxalase I (E.C. 4.4.1.5) and glyoxalase II (E.C. 3.1.2.6)] leading to increased intracellular 
levels of methylglyoxal, a toxic byproduct of the glycolysis, which ultimately brings suicide 
in cancer cells (Hollenbach et al. 2008). This pathway converts the spontaneously formed 
hemithioacetal adduct between glutathione and methylglyoxal into D-lactate and glutathione. 
The ubiquitous nature of the glyoxalase pathway emphasises its importance in general cellular 
function. However, the quantitative variability of methylglyoxal metabolism in rapidly 
proliferating cells makes it a therapeutically inevitable target. This has been well 
demonstrated in tumour cells from human colon, renal and prostate cancers and is believed to 
be because of the high proliferative growth rates of tumour cells (Creighton et al. 2003). The 
hypothesis concluding the antiproliferative effects of glyoxalse inhibitors in rapidly 
proliferating cells has also been well demonstrated in protozoan cells like Plasmodium 
falciparum. And since T. brucei are known to rapidly proliferate, demands for energy within 
cells are particularly high, resulting in high rates of glycolysis consequently producing high 
concentrations of methylglyoxal. Additionally, bloodstream-form T. brucei maintains 
respiratory rates approximately two orders of magnitude higher than those seen within 
mammalian cells (Fairlamb et al. 1986). In these parasites the glyoxalase system lacks 
glyoxalase I but they possess functionally undefined glyoxalase II. The gluthation 
hemithioacetal is also substituted by the trypanothione hemithioacetal in the process of 
methylglyoxal detoxification. Hence the thiol-containing trypanothione [N1,N8-
bis(glutathionyl) spermidine] is preferred for methylglyoxal detoxification (Ariza et al. 2006). 
 
In conclusion, the rapidly proliferative characteristic of the cells and the unique nature of the 
trypanothione-dependent glyoxalase pathway make it a novel chemotherapeutic target to treat 
trypanosomiasis eventhough they lack glyoxalase I which is substituted by a yet unknown 
enzyme (Wyllie and Fairlamb 2011). The highly proliferative capacity accompanied by a 
robust mechanism of MGO detoxification in T. brucei cells without a functional glyoxalase 
metabolism (Greig et al. 2009) prompted us to determine the effect of ethyl pyruvate and 
identify its new target in these cells. 
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1.10. HIV-1 Protease Inhibitors 
 
Initial studies have confirmed the efficacy of protease inhibitors in treatment of Trypanosoma 
cruzi, Plasmodium falciparum and Leishmania major (McKerrow et al. 1999). The 
effectiveness of HIV protease inhibitors in treating parasitic infections may similarly be 
associated to their capacity to modulate or block the cell proteasome (Parikh et al. 2005). 
Recently, it was demonstrated that HIV protease inhibitors like nelfinavir, lopinavir, indinavir 
and saquinavir have a direct effect on the causative agents of leishmaniasis including 
Leishmania amazonensis, Leishmania infantum and Leishmania major promastigotes in vitro 
(Savoia et al. 2005; Santos et al. 2009). At the same time two HIV aspartic protease 
inhibitors, saquinavir and ritonavir, have also been established in clinical use to treat malaria 
in combination with chloroquine and mefloquine (Skinner-Adams et al. 2007). Similar studies 
on efficacy and specific proteases inhibition using HIV protease inhibitors on T. brucei cells, 
however, is preliminary and remained untouched (Santos et al. 2013). 
 
These background data encouraged us to determine efficacy of two HIV-1 protease inhibitors, 
saquinavir (SQV) and ritonavir (RTV), on T. brucei cells. Besides, we will also try to identify 
the major proteases expressed as well as recognize the corresponding protease target(s) of 
these drugs in T. brucei cells. 
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2. Aim of the study 
 
Sleeping sickness is among the neglected tropical infectious diseases localized only in the 
African continent. Since its existence and recognition of the etiologic agents by scientists it 
has brought a significant impact on the social, economical and public health aspects of mainly 
the poor and remotely living communities (WHO 2013). Disease control activities including 
application of various vector control strategies and chemotherapy failed to interrupt disease 
transmission. Vector control strategies mainly require governmental coordinations, 
community participations, and mostly are not cost effective to apply in a regular basis (Kuzoe 
and Schofield 2004; Torr et al. 2011; McCord et al. 2012). Drugs are suffering from 
contraindications, parasite resistance, subspecies-specific efficacies and demand of 
hospitalization of patients for treatment (Barrett et al. 2007; Welburn et al. 2009; Spinks et al. 
2009; Steverding 2010; Jacobs et al. 2011; Alirol et al. 2013). Besides, there is no vaccine 
developed against the casusative organism because of the capability of the parasite to 
continuously change its antigenic variable surface glycoprotein (VSG) as a mechanism to 
escape the host‘s immune response. Identification of innovative drug targets and development 
of drugs which are safe, efficacious, cost effective and easy to administer is a priority research 
interest to solve the current disease control challenges. As a recent progress in this area the 
drug NECT, being recently listed under the essential drugs of WHO to treat NTDs, seems to 
fulfill the requirements except that it still encounters side effects in 68% of patients given the 
drug and is inclined to successfully treat T. b. gambiense patients when compared to T. b. 
rhodesiense infected individuals (Vincent et al. 2010; Babokhov et al. 2013; Alirol et al. 
2013). During observation of the background of most of the currently registered 
antitrypanosomal drugs, including the newly listed eflornithine in NECT combination 
therapy, they all were primarily investigated for their anticancer activities (Meyskens, Gerner 
1999; Barrett and Barrett 2000). According to the mode of action of these anticancer and 
antitrypanosomal agents, they may either affect trypanosomal DNA replication or interrupt 
enzymatic activities in glucose metabolism or act against polyamine biosynthesis. The 
probable similarities among trypanosome and cancer cells can be of their fast proliferation 
characteristics and they both possess a robust methygloxal metabolism process (Fairlamb et 
al. 1986; Creighton et al. 2003). The dicarbonyl, ethyl pyruvate, is of a typical anticancer 
agent that had also shown antifungal and antibacterial effects either through its antiglycolytic 
property or inhibition of the methylgloxal pathway [Patent N
o
. 20080300303 and 
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20100204161] and (Durak et al. 2012). The glycolytic cycle in T. brucei has a number of 
peculiarities. Nine of its glycolytic enzymes are localized within membrane bound organels 
called glycosomes and pyruvate is released out of the cells as a final product to glycolysis 
(instead of lactate in mammalian cells). This may be because the blood stream form T. brucei 
mitochondria is non-functional and they are also devoid of cytochromes. This shows the 
physiological essentiality of pyruvate export in T. brucei and a recent study has also 
confirmed the role of pyruvate transporters blockage using methyl pyruvate, an analogue to 
ethyl pyruvate, as a promising target in trypanosomes (Sanchez 2013). Since the 
antiglyoxalase activity of ethyl pyruvate (Hollenbach et al. 2008) in cancer cells may not be 
applicable because of the absence of a functional glyoxalase I enzyme in T. brucei, we may 
observe its antitrypanosomal activity either through inhibition of the the pyruvate transporters 
or probably be able to identify a new mechanism of action particularly in these cells. Our first 
hypothesis is, therefore, ethyl pyruvate, like most of the currently registered drugs that 
showed anticancer activities, may result efficient inhibition of T. brucei proliferation either 
through blockage of the unknown enzyme substituting glyoxalase I in methylgloxal 
metabolism, or inhibition of pyruvate transporters and/or other glycolytic enzymes.  
 
Our second hypothesis is based on the application of protease inhibitors in infectious agents. 
The HIV protease inhibitors are among those agents that are first used in the control of 
infectious agents. They are also observed to exhibit similar activities in other protozoal 
parasites like leishmania and plasmodium (Savoia et al. 2005; Santos et al. 2009). 
Progressively, research results have also brought ritonavir and saquinavir (the earliest known 
HIV-1 protease inhibitors) to effectively treat patients infected with chloroquine and 
mefloquine resistant plasmodium falciparum (Skinner-Adams et al. 2007). And since there is 
no previous work done in the application of these drugs in T. brucei we expect that they may 
also be effective against trypanosomes. Hence the objectives of this study project were: 
1. To determine effect of ethyl pyruvate against T. brucei cell lines in vitro. 
2. To compare effect of ethyl pyruvate to the currently available drugs pentamidin and 
suramin. 
3. To identify the specific target of ethyl pyruvate in T. brucei cells. 
4. To determine the effect of HIV-1 protease inhibitors (ritonavir and saquinavir) in T. 
brucei cells. 
5. To identify the target of ritonavir and saquinavir in T. brucei cells. 
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3. Materials and Methods 
 
3.1. In vitro cultures of Trypanosoma brucei cells 
Laboratory adapted T. b. brucei cells were cultured in complete Baltz medium which was 
composed of 82 % Baltz basic solution, 0.8% ß-mercaptoethanol, 0.8% 
penicillin/streptomycin (10,000 U/ml), and 16.4% heat inactivated fetal calf serum (FCS). 
Cells were cultured using 50 ml sterile cell culture flasks (Greiner Bio-One, Frickenhausen, 
Germany) at 37
o
C and 5% CO2 in 100% humidified environment. The medium was changed 
every 2-3 days. 
 
3.2. Cell proliferation/viability assay 
The AlamarBlue® cell proliferation assay has been employed to measure the metabolically 
active cells. The principle behind this assay relates to the fact that metabolically active cells 
create a reducing environment that promotes the conversion of resazurin (non-fluorescent) to 
resorufin (highly fluorescent). The absorbance was measured using an ELISA reader/96-well 
multiscanner (Tecan, Crailsheim, Germany) at ex550/em630 nm. 
 
3.3. Effect of drugs on proliferation of trypanosomes 
The concentration-response assay was performed in 96-well cell culture plates to which 100 
µl of cell suspension (2x10
4
 cells), 100 µl of drug at increasing concentrations and 20 µl of 
AlamarBlue® was added. Control wells contained 200 µl of equal number of cells in fresh 
medium without drugs. The change in absorbance was recorded at the 48
th
 hr of incubation. 
The drugs or compounds used were ethyl pyruvate and L-ethyl lactate, Pentamidine-
isethionate, suramin, diethyl oxalate, butyl L-lactate, isobutyl D-lactate, benzyl (S)-
lactate,methyl (S)-lactate and pyruvate. 
 
3.4. Response of trypanosome cells to ethyl pyruvate and pentamidine 
Time-dependency test was done in 24-well plates containing 1 ml of cell suspension (2x10
5
 
cells/well) and 100 µl of ethyl pyruvate at variable concentrations (1 to 20 mM), or an equal 
volume of fresh medium (control). Cells were incubated for 24 hrs at 37
o
C in a humidified 
environment containing 5% CO2. For cell counting, a Neubauer hemacytometer (Marienfeld, 
Lauda-Königshofen, Germany) was used. The number of moving cells was recorded after 1 
hr, 3 hrs, 6 hrs and 24 hrs of incubation, respectively. Tests were done in triplicates and the 
mean and standard deviation was calculated. 
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3.5. Recovery of cells exposed to ethyl pyruvate and pentamidine 
Cell recovery test was done using 1 ml of cells (2x10
5
 cells/ml) seeded into a 24-well plate  to 
which was added 100 µl of ethyl pyruvate (1 to 20 mM) or pentamidine (12.8 to 128 nM). As 
a negative control 100 µl of fresh medium without drugs was added. Cells were exposed to 
ethyl pyruvate and pentamidine for 3 hrs and 48 hrs, respectively. Aliquots were removed and 
centrifuged (1500 rpm, 10 min, 5
o
C). The supernatant was carefully removed and the 
sediment was re-suspended with 1 ml fresh medium. Re-incubation of cells in 24-well plates 
was done for another 48 hrs. Cells were counted at the beginning of re-incubation and at 1 hr, 
3 hrs, 6 hrs, 24 hrs, and 48 hrs afterwards. The tests were done in triplicate. 
 
3.6. In vitro drug-resistance test 
Primarily, cells were treated with sub-lethal concentrations (1 and 2 mM) of ethyl pyruvate 
for 30 days in separate cell culture flasks. The medium and the drug were changed every two 
days. The control cells were left in fresh medium without ethyl pyruvate. On day 31
st
, 100 µl 
of 2x10
4
 cells per well were seeded in a 96 well plate. Each cell group was treated with ethyl 
pyruvate at increasing concentrations ranging from 1 to 20 mM. Controls were incubated in 
fresh medium without ethyl pyruvate. To each well 20 µl of the AlamarBlue® reagent and 
absorbance was recorded after 48 hrs of incubation.  
 
3.7. Phase contrast microscopy and video recording  
Culture flasks containing 5 ml of cells (10
7 
cells/ml) were exposed to a final concentration of 
5 mM ethyl pyruvate and 128 nM pentamidine. A control flask contained equal number of 
cells in fresh medium without drugs. All the cells were incubated for 3 hrs. For video 
recording, the 5 ml cell suspension (10
7 
cells/ml) was poured into a Nunclon culture dish 
(Sigma-Aldrich, Taufkirchen, Germany) with a bottom partially replaced by a glass-slide to 
increase imaging quality. The dish was closed with a custom made lid equipped with a CO2 
adapter to allow for 5% CO2 supply in air. Cells were observed for three hours on an inverted 
phase contrast microscope (DMIRB, Leica) endowed with a 20x Objective (0.4 NA) and a 1x 
C-mount. The microscope was enclosed by a self-made thermo-box kept at 37
o
C to provide 
usual cell culture conditions. Videos were recorded every hour for untreated and pentamidine 
treated cells. For those cells treated with 5 mM ethyl pyruvate video recording was done 
every 30 min. The recordings were taken using a Phytec FireWire-CAM-111H with a frame 
rate of 15 fps. Each video sequence lasts 2 min.  
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3.8. Cell extracts preparation and protein concentration determination 
To prepare cell extracts the cell pellet was first re-suspended at 1:4 ratio in a lysis buffer 
containing [25 mM Tris, 2 mM PMSF, 10% Glycerol, 1% Tritonx100, 2 mM EDTA and 
freshly added 0.3% protease inhibitor cocktail] at pH 8.03. The suspension was repeatedly 
vortexed every 1-2 min within 15 min duration. The cell sediment was always kept on ice. 
Then the mix was centrifuged for 15 min at x13000g in 5
o
C. The supernatant was carefully 
pipetted into a new eppindorf tube and the sediment was discarded. The protein content of 
samples was determined by means of the Bradford method (Bradford 1976).  
 
3.9. Determination of the ATP content 
Cellular ATP content was determined by means of the CellTiter-Glo® luminescent cell 
viability assay according to the manufacturer‘s instructions (Promega, Madison, USA). 
Briefly, cells were cultured in 24-well plates (4x10
4
 cells/well) in the absence or presence of 
ethyl pyruvate (1 to 20 mM) and incubated at 37
o
C and 5% CO2 for 3 hrs. Cells were then 
mixed with test reagents and luminescence was read. A standard curve was prepared from 
ATP (10 nM to 1 μM ) in medium to determine the actual ATP level in cells.  
 
3.10. Enzyme activity assays 
 
3.10.1. Hexokinase 
The principle of the test on the hexokinase (EC 2.7.1.1) activity assay was based upon the 
reduction of NAD
+
 through a coupled reaction with Glucose-6-phosphate dehydrogenase. The 
increase in absorbance was determined spectrophotometrically at 340 nm wavelength 
according to Bigl et al. (1999). Briefly 100 µl of cell extract was first incubated in 10mM 
ethyl pyruvate and the reaction was started bz adding the lysate in 3 ml of reaction mix 
containing Tris buffer (pH 8.0), 13.3 mM MgCl2, 0.67 M glucose, 16.5 mM ATP, 6.8 mM 
NAD and Glucose-6-phosphate dehydrogenase. Increase in absorbance was recorded every 1 
min for 5 min. 
 
3.10.2. Phosphofruktokinase 
The activity of phosphofruktokinase (EC 2.7.1.11) in T. brucei was measured at 340 nm in a 
coupled assay with aldolase (EC 4.1.2.13), glycerol-3-phosphate dehydrogenase (EC 1.1.1.8) 
and triosephosphate isomerase (EC 5.3.1.1) according to Kopperschläger et al. (1993). 
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Activity of phosphofructokinase was measured using 100 µl of T. brucei cell extract treated 
with 10 mM ethyl pyruvate for 30 min.  
 
3.10.3. Pyruvate Kinase  
To determine kinetics in pyruvate kinase activity we first applied the indirect coupled assay 
using lactate dehydrogenaseactivity as described by Callens et al. (1991). However, ethyl 
pyruvate has been found to act as a substrate probably because it is analogous to pyruvate 
itself resulting in a concentration dependent concomitant increase in lactate production and 
NADH reduction to NAD+. Hence the activity of pyruvate kinase (EC 2.7.1.40) was 
evaluated by measuring the ATP production using the CellTiter-Glo® Luminescent assay 
following the manufacturer‘s instructions (Promega, Madison, USA).  
 
To determine the inhibition of PK activity in the cell extracts the ATP production reaction 
was initiated using a reaction mix of 200 mM Tris/HCl buffer (pH 7.0), 15 mM MgCl2, 2 mM 
ADP and 3 mM phosphoenolpyruvate and 10 mM ethyl pyruvate. To start the reaction 10 µl 
of the crude cell extract (1.17 mg/ml protein) was finally added. PK activity was expressed as 
(nM ATP/µl/s). 
 
The PK kinetics assay was performed at increasing concentrations of phosphoenolpyruvate 
(0.1 to 3 mM) as well as ethyl pyruvate at 5, 10 and 15 mM as an inhibitor. Purified PK-1 
from rabbit muscle (stock of 200 U/mg) was used for the test. The activity measurements 
were performed for 10 min at 20 °C. The ATP luminescence measurement was done in a 96-
well white opaque plate (Greiner, Frickenhausen, Germany) at 250 milliseconds ATP 
luminescence integration time using SoftMax Pro 5.3 software. Finally, the Vmax, Km and Ki 
values were calculated to characterize the inhibitory effect of ethyl pyruvate at the enzyme. 
The observed data in the presence and absence of ethyl pyruvate were fit simultaneously for a 
competitive enzyme inhibition model shown by the equation below. Nonlinear regression 
fitting was accomplished with use of SIGMAPLOT (Systat Software Inc.) applying a 
weighting function of 1/Y
2
. PK activity was expressed as (nM ATP/µl/s). 
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3.10.4. Methylglyoxal reductase 
Methylglyoxal reducing activity was determined in a mixture of 10 mM methylglyoxal, 100 
mM Tris/HCl buffer (pH 7.0), 0.1 mM NADPH and 10 µl cell lysate at 25
o
C. The activity 
was determined by measuring the rate of decrease in absorbance at 340 nm, which was 
recorded with a spectrophotometer (SPECORD 50, Jena, Germany) using WinAspect 
software and was expressed as specific activity (µmol NADP
+
 x min
-1 
x mg protein
-1
) (Murata 
et al. 1985; Ghoshal et al. 1989). 
 
3.11. Effect of ethyl pyruvate on human red blood cells 
Human heparinized blood (5 ml) was centrifuged at 2000 rpm for 15 min and supernatant was 
removed. The cells were washed three times with 20 mM sodium phosphate, 150 mM sodium 
chloride (PBS), pH 7.4. Human red blood cells (5x10
5
) were mixed to 2x10
5
 T. brucei cells in 
5 ml fresh medium in a 25 cm
2
 culture flask. Cells were incubated at 37
o
C in 5% CO2 for 24 
hrs. Aliquots (1 ml) were taken and distributed into 24-well plates and incubated with 100 µl 
medium containing increasing concentration of ethyl pyruvate (1 to 15 mM). Controls 
contained cells without ethyl pyruvate but 100 µl of fresh medium. The cells were then 
incubated for 3 hrs. Trypanosome cells and blood cells were counted and the release of 
haemoglobin in the supernatant after cell centrifugation was measured spectrophotometrically 
at 540 nm. As a positive control a cell suspension of red blood cells was hemolysed using 
ultra-sonication to obtain complete hemolysis of a similar blood specimen not containing 
ethyl pyruvate.  
 
3.12. Response of T. brucei cells to Ritonavir and Saquinavir exposure 
Time dependency test was done in 24-well plates where 1 ml of cell suspension (2x10
5
 
cells/well) plus 100 µl of ritonavir (Cat.4622; Lot. 110018) or saquinavir (Cat. 4658; Lot. 
01989) at increasing concentrations (5 to 100 µM range) or 100 µl of fresh medium 
containing 1% DMSO (control). The mixtures were incubated at 37
o
C in humidified 
environment containing 5% CO2 for 24 hrs. Prior to cell counting the plate was slowly shaken 
in slow circular motion to homogenise cell distribution within the growing medium in each 
well. After certain time gaps (1, 3, 6 and 24 hrs) of incubation, a volume of 10 µl of the cell 
suspension was taken for counting of motile cells using a Neubauer hemacytometer 
(Marienfeld, Germany). All tests were done in triplicates unless otherwise indicated.  
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3.13. Zymography  
A non-reduced 12% SDS polyacrylamide gel (PAGE) co-polymerized with 1% gelatin 
substrate was used for detection of protease activity T. brucei cell extracts. Prior to running 
 the SDS PAGE, the cell extract was mixed with equal volume of SDS sample buffer in a 
non-reducing condition. Then 40 µl (18.3 µg protein) of cell extract-sample buffer mix was 
added to each lane. Protein marker (each 6 µg per lane) was used as a molecular standard. The 
electrophoresis was run at 125 V for 1.5 hrs. The gel was then slowly removed from the gel 
chamber and incubated at 22
o
C for 30 min with an aqueous solution of 2.5% Triton X-100 for 
renaturation and removal of SDS from the gel. The gel was then incubated again at 22°C in 
developing buffer containing 8 mM CaCl2 in 50 mM Tris, pH 8.0 for another 30 min. The 
developing buffer was changed and the zymogen was incubated overnight with fresh 
developing buffer at 37
o
C. The gel was then stained by 0.05% Commassie Brilliant Blue 
R250 for 3 hrs. Destaining was achieved by incubation with a mixture of water/ 
methanol/acetic acid (50:40:10v/v) for 30 min. The presence of active proteases was indicated 
by white bands when contrasted with the blue background of the stained gel.   
 
3.14. Application of zymography for identification of proteases in T. brucei cells 
To detect different species of proteases in the cell extract by zymography, the gels were 
separately incubated with either 20 mM EDTA (pH 8.0), 5mM PMSF or 5 mM iodoacetamide 
for inhibition of metalloproteinases, serin proteases or cysteine proteases, repectively. Finally, 
the gels were scanned and the protein bands showing active substrate digestion in the control 
gels were white colored but those inhibited by the respective specific protease inhibitors were 
blue colored bands.  
 
3.15. Zymography using Ritonavir and Saquinavir 
The same protocol as the zymography (section 3.13) was applied except that 100 µM RTV 
and 100 µM SQV are applied. Briefly, the respective sample gels were incubated in 100 µM 
RTV and 100 µM SQV in a 50 ml fresh developing buffer (50 mM Tris, pH 8.0 containing 8 
mM CaCl2) overnight at 37
o
C. The control gel was incubated in a developing buffer 
containing 1% DMSO without either of the HIV-1 protease inhibitors. Finally the gels were 
scanned in a computer scanner. 
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3.16. Statistical Data Analysis 
The data was analysed using Graphpad Prism software version 5.0 (GraphPad Software Inc., 
San Diego, USA) and SPSS version 15.0. Statistical comparison of difference between means 
has been done using two-tailed t-test. Results were considered statistically significant when p- 
value was less than 0.05. The IC50 values were determined using the trend line linear formula 
in MS-Excel 2010 software. Video recording and phase contrast microscopy was used to 
show the time dependent efficacy of ethyl pyruvate on T. brucei cells when compared with 
the controls using pentamidine as a reference drug. 
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4. Results 
 
4.1. Effect of ethyl pyruvate on T. brucei cells proliferation and their energy metabolism 
At first we analysed the effect of ethyl pyruvate and its reduced form, L-ethyl lactate, at 
proliferation of the T. brucei cells. The proliferation was measured by incubation of the cells 
with increasing concentration of the drugs (1 to 20 mM). The sample without the drugs was 
considered as blank. The result revealed that ethyl pyruvate effectively inhibits the cell 
proliferation with an IC50 of 2.03 mM and the minimum ethyl pyruvate concentration that 
gives maximum inhibition was 5 mM (Fig. 5A). Interestingly, L-ethyl lactate did not inhibit 
the cells (Fig. 5B). This is surprising, because the difference between the two compounds is 
just the presence of one additional proton in L-ethyl lactate.  
 
Next we analysed the effect of ethyl pyruvate at different time points. The proliferation of 
trypanosomes was completely inhibited at 5 mM ethyl pyruvate after 3 hrs of incubation 
indicating that it kills trypanosomes within a short time of contact. At lower concentrations of 
ethyl pyruvate the inhibitory effect was reduced and no inhibition was observed at 
concentrations <1 mM ethyl pyruvate (Fig. 5C). 
 
To analyse whether ethyl pyruvate inhibits trypanosomes irreversibly, trypanosomes were 
incubated with variable concentrations of ethyl pyruvate for 3 hrs, then the medium was 
removed and finally the cells were replenished in fresh medium in the absence of ethyl 
pyruvate for 24 hrs (Fig. 5D). The results indicated that cells exposed to low concentration of 
the drug (≤ 2.5 mM) kept vital, continued to proliferate and were capable of recovering from 
the cytotoxic effect of ethyl pyruvate. In contrast, at a concentration ≥5 mM the cells were 
irreversibly damaged, and had completely lost their cellular integrity.  
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Figure 5. Effect of ethyl pyruvate and L-ethyl lactate on T. brucei cells proliferation. Cell 
proliferation/viability assay has been done in 96-well cell culture plates containing 2x104 cells, medium and 
drugs in a volume of 200 µl. (A) Ethyl pyruvate, (B) L-ethyl lactate, (C) Time dependency test was performed in 
24-well plates. Ethyl pyruvate concentrations used were: 0 mM (▀), 1 mM (▲), 2.5 mM (x) and 5 mM (□). (D) 
Cell recovery test was performed using a 24-well plate. Ethyl pyruvate concentrations used were: 0 mM (▀), 1 
mM (▲), 2.5 mM (▼), 5 mM (□) and 10 mM (+). In all cases cells were incubated at 37 °C containing 5% CO2 
in a 100% humidified environment. * p<0.05. 
 
In addition to the comparison of ethyl pyruvate with ethlyl L-Lactate it has also been 
compared with other structurally similar dicarbonlyl compounds (Fig. 6). Related compounds 
with longer chains act better than ethyl L-lactate. Compounds like pyruvate and methyl (S)-
lactate, however, had almost no effect on T. brucei cells proliferation. Among all the 
compounds tested benzyl (S)-Lactate and diethyl oxalate were observed to significantly 
inhibit T. brucei cells at 5 mM. However furher analysis of the compounds regarding safety 
indicated that they were not good candidates when compared with ethyl pyruvate. Diethyl 
oxalate had even showed a corrosive characteristic when in contact with some materials. 
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Figure 6. Comparison of the anti-proliferative effects of different dicarbonyls and monocarboxylates with 
ethyl pyruvate in T. brucei cells. The same protocol has been employed as in figure 5(A) and (B). The chemical 
structure of compounds was cited from pubchem compounds database. *p-value<0.05. 
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4.2. In vitro drug resistance 
In an in vitro drug resistance test the T. brucei parasites were cultured in medium containing 
sub-lethal concentrations of ethyl pyruvate, 1 mM and 2 mM, for 30 days. The cells were then 
subjected to increasing concentrations of ethyl pyruvate (1 to 20 mM). The result finally re-
confirmed that the cells failed to develop resistance against ethyl pyruvate during the specific 
period of exposure (Fig. 7).  
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Figure 7. Drug resistance test in T. brucei using sublethal concentrations of ethyl pyruvate. Cells were 
treated with sub-lethal concentrations at 1 mM and 2 mM of ethyl pyruvate for 30 days in separate cell culture 
flasks. The medium and the drug were changed every two days. The control cells were left in fresh medium 
without ethyl pyruvate. On day 31st, 100 µl of 2x104 cells per well were seeded in a 96-well plate. Each cell 
group was treated with ethyl pyruvate at increasing concentrations ranging from 1 to 20 mM. Absorbance was 
recorded at 48 hrs of incubation.  
 
4.3. Comparative anti-proliferative effects of pentamidine and suramin 
Currently, the registered first-stage sleeping sickness treatment drugs are pentamidine and 
suramin (Babokhov et al. 2013). Pentamine belongs to the class of aromatic diamidines 
previously designed for prevention and treatment of pneumocystic pneumonia, leishmaniasis 
and first stage infection with T. b. gambiense. Suramin is an analogue of Trypan Blue used for 
treatment of sleeping sickness since many years (Morgan et al. 2011b). It was our intent to 
compare the anti-trypanosomal activity of ethyl pyruvate with these standard drugs used in 
sleeping sickness treatment. As demonstrated in figure 8A the proliferation of trypanosomes 
is inhibited by pentamidine at quite lower concentrations compared to ethyl pyruvate. When 
we compare the two state-of-the-art drugs, suramin was found to be less effective because its 
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anti-proliferative impact became first apparent at concentrations within the range of 100 nM 
and 1 µM but there was no complete inhibition even after 48 hrs of incubation at the 
maximum applied concentration (3855 nM) (Fig. 8B). The time-dependency test revealed 
measurable effects of pentamidine only at 48 hrs of incubation (Fig. 8C). The death rate of 
pentamdine treated T. brucei indicated that more than 80% of the cells could be killed after 24 
hrs of incubation and almost complete inhibition of cell proliferation was obtained only at the 
highest concentration of 128 nM after 48 hrs (Fig. 8C). Compared to pentamidine, ethyl 
pyruvate, however, was a very fast acting and irriversible growth inhibitor. 
 
The cell recovery tests with pentamidine confirmed its cytostatic effect at 64 nM and full 
cytotoxicity (non-recovery) at concentrations ≥128 nM at long term incubation (Fig. 8D).  
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Figure 8. Anti-proliferative effects of pentamidine and suramin on T. brucei. Cell proliferation/viability was 
assayed as described in figure 1 with the exception of the use of (A) pentamidine and (B) suramin at variable 
concentrations. (C) Time dependency of anti-proliferative effects of pentamidine at variable concentrations (12.8 
to 128 nM). Controls contain 100 µl of fresh medium instead of a drug. Pentamidine concentrations used were: 0 
nM (▀), 12.8 nM (▲), 51.2 nM (▼), 64 nM (♦) and 128 nM (●). (D) Recovery test of T. brucei cells exposed to 
pentamidine was done in 24-well in the presence of pentamidine (12.8 nM to 128 nM). Pentamidine 
concentrations used were: 0 nM (▀), 12.8 nM (▲), 51.2 nM (▼), 64 nM (♦) and 128 nM (●).  The result is mean 
of three measurements (n=3), *p<0.05. 
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4.4. Effect of ethyl pyruvate at cellular ATP level  
The sudden loss of viability of trypanosomes at short-time incubation with ethyl pyruvate 
prompted us to look at the energy budget of the cells assuming that ATP depletion may be a 
possible cause of its extreme cytotoxicity against T. b. brucei. Our results revealed that the 
cellular ATP level was significantly hampered. There was a clear concentration-dependent 
loss in cellular ATP in the presence of ethyl pyruvate (Fig. 9). The result indirectly 
demonstrated that ethyl pyruvate might hamper the glycolytic pathway which is the sole 
energy- rich phosphate delivering pathway in trypanosomes.  
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Figure 9. Effect of ethyl pyruvate at cellular ATP level in T. brucei. (A) Trypanomomes (3x105 cells/well) 
were cultured in 24-well plates in the absence (control) or presence of ethyl pyruvate (1 to 20 mM) and 
incubated for 3 hrs at 37oC in 5% CO2. After incubation, cells were centrifuged at 1500 rpm for 10 min and 
supernatant was removed. The cell sediment was re-suspended smoothly in 500 µl of fresh medium. From this 
suspension 50 µl (equivalent to 3x104 cells) was added into a 96-well black opaque walled plate in duplicates 
and mixed with 50 µl of test reagent per well. Luminescence was read at 560 nm emission maximum. The actual 
ATP level was calculated from the trend line formula of the standard curve (n=3), *p<0.05. 
 
4.5. Effect of ethyl pyruvate on the activity of glycolytic enzymes 
From results shown above, a possible inhibition of the glycolytic enzymes necessarily 
involved in ATP production steps in trypanosomes by ethyl pyruvate was hypothesized. The 
enzymes critical for the survival of blood stream form trypanosomes that might directly affect 
the ATP production are hexokinase-1 (HK-1), phosphofructokinase (PFK) and pyruvate 
kinase (PK) (Kerkhoven et al. 2013). Therefore, we analyzed the specific activity of these 
glycolytic enzymes in trypanosome extracts in the absence and presence of 10 mM ethyl 
pyruvate. This concentration was selected because of its maximum effects obtained in all tests 
so far. As demonstrated in Figures 10A and B, ethyl pyruvate was unable to inhibit the 
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activity of HK and PFK in cell extracts. In contrast to these enzymes we were able to 
demonstrate a statistically significant inhibition of PK at 10 mM EP (Fig. 10C).  
 
 
Figure 10. Effect of ethyl pyruvate on the activity of glycolytic enyzmes of T. brucei. (A) Specific activity of 
hexokinase in T. brucei cell extracts in the absence and presence of 10 mM ethyl pyruvate. (B) Specific activity 
of phosphofruktokinase in T. brucei cell extracts treated with 10 mM ethyl pyruvate for 30 min. C) Pyruvate 
kinase activity in trypanosome cell extracts. The reaction was initiated by adding 10 µl of the crude cell extract 
(1.17 mg/ml protein) to an assay containing 1 mM or 10 mM ethyl pyruvate and ATP level was determined 
according to the manufacturer‘s instructions (Promega, Madison, USA). * p<0.05 
 
In order to prevent the influence of cellular metabolites of the extract on PK kinetics we used 
purified PK from rabbit muscle for detailed kinetic studies. Thus, we analyzed the substrate-
enzyme activity relation in the absence and presence of variable concentrations of ethyl 
pyruvate and phosphoenolpyruvate (PEP), respectively. Figure 11 shows the Km (± SD) 
values for the control (without ethyl pyruvate), and at different ethyl pyruvate concentrations 
in dependence to the substrate concentration. From the obtained saturation curves the Ki value 
was calculated. Data analysis revealed a competitive inhibition of PK activity by ethyl 
pyruvate with a Ki= 3.0±0.29 mM.  
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Figure 11. Competitive inhibition of pyruvate kinase activity by ethyl pyruvate. Enzyme activity was 
measured by following up the production of ATP from the substrates phosphoenolpyruvate (PEP) and ADP as 
described in Materials and Methods. Enzyme activity expressed as nmole ATP/min was recorded in dependence 
of increasing substrate concentrations (PEP) in the absence and presence of ethyl pyruvate, Control (●) 
(KM=0.22±0.02 mM), ethyl pyruvate at 5 mM (○) (KM=0.51±0.03mM), 10 mM (◊) (KM=1±0.08mM) and 15 mM 
(∆) (KM=1.4±0.08mM) A pure enzyme from rabbit muscle (200 U/mg) was used for the experimental setup to 
avoid contamination bias in our cell extract. The Km and Ki values were calculated by SIGMAPLOT (Systat 
Softwarwe Inc.).  
 
4.6. Phase contrast microscope video imaging of ethyl pyruvate exposed T. brucei cells 
To visualize the effectiveness and fast acting property of ethyl pyruvate we performed video-
recording and phase contrast microscopy of the trypanosome. The videos: S1 Video represent 
the control cells; S2Video represents 128 nM treated cells and S3 Video represents 5 mM 
ethyl pyruvate exposed cells. The videos showed the features of morphological changes of 
trypanosoma cells throughout the 3 hrs incubation time. The cell motility status generally 
indicates how fast the drug acts against survival of these cells. The fast acting property of 
ethyl pyruvate can easily be confirmed by slow or static motion of the previously active 
motile cells. The cytotoxic effect of ethyl pyruvate started already after 1 hr of exposure and 
complete inhibition of cell motility finally leading to cell death was observed after 3 hrs of 
incubation at 5 mM. In contrast to ethyl pyruvate, no visible effect was exhibited when 
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pentamidine was applied at the highest toxic concentration of 128 nM within the same time 
range.  
 
S1 Video. Phase contrast microscope video of live actively moving T. brucei cells. A control flask contained 
(107 cells/ml) in 5 ml fresh medium without drugs and assigned as a negative control. The cells were incubated 
for 3 hrs and videos were recorded every hour. (For details regarding the method please see the Materials and 
Methods section). A free downloadable version of Freemake Video Converter.exe software was used to 
sequentially put the video files together in one video file (Link: http://youtu.be/KIK_zZnJrCM) (login ID: 
netsanetworku; password: netsanet32000). 
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S2 Video. Phase contrast microscope video of pentamidine treated T. brucei cells. A test flask contained (107 
cells/ml) in 5 ml fresh medium treated with 128 nM pentamidine and treated as shown in Video S1. (Link: 
http://youtu.be/xj5kKmWpz6o) ((login ID: netsanetworku; password: netsanet32000) 
 
 
S3 Video. Phase contrast microscope video of ethyl pyruvate treated T. brucei cells. A test flask contained 
(107 cells/ml) in 5 ml fresh medium treated with 5 mM ethyl pyruvate and treated as shown in Video S1 (Link: 
http://youtu.be/xp72G_wZ8EU) (login ID: netsanetworku; password: netsanet32000). 
 
4.7. Cytotoxicity of ethyl pyruvate to the normal human erythrocytes 
To prove whether ethyl pyruvate displayed advantageous selectivity of action against 
protozoa cell we performed ex vivo experiments by co-incubation of human red blood cells 
with the trypanosomes and ethyl pyruvate for 3 hrs, followed by cell counting and analysis of 
the red blood cell hemolysis. As expected, at 5 mM ethyl pyruvate only few motile cells were 
observed while no significant change was seen in the red blood cell count (Fig. 12A). The 
latter finding was substantiated by a non-significant release of hemoglobin from the red blood 
cells that remarks the drug´s safety at least toward human erythrocytes when compared with 
the OD reading of totally hemolysed blood cells used as a positive control (Fig. 12B). 
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Figure 12. Cytotoxicity evaluation of ethyl pyruvate on human erythrocytes. (A) 5-6x105 red blood cells 
(RBCs) were mixed to 2x105 T. brucei cells in 5 ml fresh medium in a flask. Cells were first incubated at 37oC in 
5% CO2 for 24 hrs. Out of this 1 ml-aliquots were distributed into 24-well plates and incubated with 100 µl of 
increasing concentration of ethyl pyruvate (1-15 mM). Controls contained cells without ethyl pyruvate but 100 
µl of fresh medium. The cells were then re-incubated for 3 hrs. Then, the number of trypanosomes and human 
erythrocytes was counted in a microscope using haemocytometer. (B) Effect of ethyl pyruvate on RBC 
hemolysis was determined by measuring the optical density of the medium containing the T. brucei and RBC co-
incubated for 3 hrs. Before measurement the cells were spinned down by centrifugation. 100% hemolysis of 106 
cells/ml using an ultrasonicater was considered as the positive control (labelled as ‗Control‘). Cells without ethyl 
pyruvate was the negative control (labelled as ‗Blank‘) 
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4.8. Effect of HIV-1 protease inhibitors on proliferation of T. brucei cells 
Our results demonstrated that ritonavir (RTV) at concentrations above or equal to 50 µM was 
most effective killing more than 80% of the cells in 24 hrs of exposure (Fig. 13A). Saquinavir 
(SQV) resulted in similar growth inhibition starting from the 20 µM concentration (Fig. 13B).  
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Figure 13. Response of T. brucei cells exposed to ritonavir (A) and saquinavir (B). 1 ml of 2x105 cells per 
well in a 24-well plate is applied at the beginning of the experiment.In both cases  cells were exposed to either of 
the two drugs at variable increasing concentrations and cell count was done at variable time points within 24 hrs 
of incubation time.  
 
In the AlamarBlue®cell proliferation assay the concentration dependent effect of these two 
drugs was observed using 96-well plates. RTV and SQV resulted in a significant inhibition 
(p<0.05) at 10 µM concentration (Fig. 14A). SQV acts a little better than RTV resulting 
equivalent effects with a lower IC50 (Fig. 14B). Figures 13 and 14, therefore, confirmed that, 
both RTV (IC50=12.23 µM) and saquinavir (IC50=11.49 µM) can effectively inhibit T. brucei 
cells proliferation. 
 
Figure 14. The anti-proliferative effect of ritonavir (A) and saquinavir (B) in T. brucei cells. 2x104 cells per 
well were incubated with each inhibitor at increasing variable concentrations within 5 to 100 µM range. 
AlamarBlue® proliferation assay was employed and absorbance was measured at ex550/em620 nm wavelength. 
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4.9. Identification of the major proteases in T. brucei cell extracts 
To determine targets of these two drugs it was first important to identify the major proteases 
available in T. brucei cells. As indicated in figure 10, we were able to identified two major 
proteases that can clearly be seen as white bands in the lanes of the control gel (n=3) with 
molecular masses of ~66 kDa and ~29 kDa. The next question was to identify the type or 
class of these proteases using metallo-, serine- and cysteine- specific protease inhibitors. The 
second gel (n=3) in figure 15 indicates activity inhibition of proteases by 
ethylendiamintetraacetat (EDTA) at the ~66 kDa position confirming it is a metallo-protease. 
The 3
rd
 gel indicated inhibition of the ~29 kDa protease activity by the iodoacetamide, 
showing it is a cysteine protease. Supporting this result PMSF also inhibited the ~29 kDa 
protease, only partially, affirming it is a papain family cysteine protease type. Those bands at 
the ~29 kDa are thicker than the band size of the ~66 kDa proteases showing the cystein 
proteases are also proportionally more abundant or showed better gelatinolytic activity than 
the metallo-proteases in T. brucei cells. This zymographic data, therefore, indicates that the 
two major proteases, that are clearly expressed using gelatin as a substrate, are papain-like-
cystein proteases and metallo-proteases (Fig. 15).  
 
 
Figure 15. Identification of proteases in T. brucei cell extracts. T. brucei cell extract was first mixed with 
equal volume of sample buffer without a reducing agent and 40 µl of sample containing 18.3 µg of protein 
concentration was loaded in each lane in an SDS-substate gel before running the electrophoresis. A Roti-protein 
marker was used as a standard. Control lanes (n=3) showed the proteases expressed as white bands at the ~66 
kDa and ~29 kDa level. Application of 20 mM EDTA (n=3 lanes) showed inhibition of the white bands 
expression at the ~66 kDa level indicating that this is a metalloprotease. Application of 5 mM idoacetamide (n=3 
lanes) on the other hand inhibits expression of the ~29 kDa protease indicating that this is a cysteine protease. At 
the last gel (n=3 lanes) 5 mM PMSF was applied and showed partial inhibition of the ~29 kDa protease telling 
that this is a papain-like-cysteine protease.  
 
 
 
 
 
 
[Netsanet W. (2015). PhD Dissertation] 44 
 
4.10. Effect of HIV-1 protease inhibitors on the proteolitic activity of the major 
proteases in T. brucei  
As can be seen in figure 16, the effect of HIV-1 protease inhibitors, ritonavir and saquinavir, 
on activity of these two major proteases has been tested. The result demonstrates that there is 
no inhibition of activity of these proteases by ritonavir as well as saquinavir.  
 
 
Figure 16. Inhibition of the identified proteases using ritonavir and saquinavir. Roti-protein marker (6 µg) 
is used in the standard lane. Control lanes (n=2) show the metallo-proteases expressed as white bands at the ~66 
kDa and papain like cysteine proteases at the ~29 kDa position. Exposure of the proteases with 100 µM RTV 
and 100 µM SQV at the last two gels (each n= 3 lanes) indicated that there is no inhibition of both the metallo- 
and cysteine-proteases of T. brucei cells. 
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5. Discussion 
There are limited drugs currently in use against African trypanosomiasis. Most of them are 
older than 40 years and are associated with severe side effects (Stich et al. 2013). 
Even though the genome of trypanosomes has been sequenced many years earlier, this has not 
let to new breakthroughs in the treatment of HAT (Berriman et al. 2005; Ackermann et al. 
2012). As for other parasitic diseases, the major constraint in vaccine development against 
trypanosomiasis is the ability of the parasite to undergo extreme antigenic variation (Hall and 
James et al. 2013). Because of this there is yet no effective vaccine available for humans and 
animals. 
 
A number of drugs such as suramin and nifurtimox with anti-trypanosomal activity have been 
applied in cancer therapy (Meyskens and Gerner 1999; Watson et al. 2012; Borges et al. 
2014). The molecular targets of these drugs are not yet clear. Some drugs are suggested to 
modulate the generation of reactive oxygen species which damage cellular components such 
as DNA, membrane lipids and proteins (Docampo et al. 1981), others modify activity of 
enzymes such as ornithine decarboxylase (Phillips et al. 1987), or pyruvate dehydrogenase 
kinase (Morgan et al. 2011a).  
 
A common feature between tumor cells and trypanosomes is the high consumption of glucose. 
To produce ATP, the bloodstream form T. brucei dependents solely on glycolysis (Besteiro et 
al. 2005). To cover its high energy demand, the parasite uses the host‘s glucose for ATP 
production. When this dependence on glycolysis for ATP production is cross linked with their 
reduced mitochondrial function, it will limit the metabolic options available to the parasite. 
Most of the enzymes that participate directly in glycolysis are organized in membrane bound 
organelles called ―glycosomes‖ or peroxisome like organelles (Michels et al. 2006). Through 
a cascade of reactions these enzymes, under aerobic conditions, convert glucose to 3-
phosphoglycerate. In the cytosol the pyruvate kinase will finally metabolise 
phosphoenolpyruvate to pyruvate concomitantly producing their net ATP. Pyruvate is then 
released from the cell because of the lack of a canonical L-lactate dehydrogenase (Clarkson et 
al. 1989). 
 
Analogously, many tumor cells exhibit a high aerobic glycolysis combined with a restricted  
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oxidation within the respiratory chain (Warburg 1956; Masui et al. 2014). Instead of pyruvate 
as in trypanonomes, L-lactate is produced by tumor cells which provide growth advantage 
because of the repression of the immune system and promotion of cell invasion (Gatenby and 
Gillies 2004).  
 
Normally, the high glycolytic throughput of tumor cells leads to accumulation of the toxic 
intermediate methylglyoxal by non-enzymatic degradation of trioses. This reactive aldehyde 
is known to modify DNA, protein and lipids and can induce mutagenesis, apoptosis and death 
of cells. To prevent the glycolysis-driven cellular damage a ubiquitous detoxification pathway 
comprised of glyoxalase I and glyoxalase II, converts methylglyoxal into D-lactate. Thus, 
glyoxalases are permissive for growth of tumors with high glycolytic rate. This may explain 
why these enzymes are considered as possible target in tumor therapy. Recently, we have 
shown that compounds containing a dicarbonyl structure such as ethyl pyruvate, curcumin 
and different polyphenols inhibit glyoxalases and kill tumor cells (Santel et al. 2008; 
Baunacke et al. 2014). 
 
These findings prompted us to study the effect of ethyl pyruvate on trypanosomes which, like 
most tumor cells, have a high glycolytic rate. However, we are aware that T. brucei lacks 
glyoxalase I and uses trypanothione instead of glutathione unlike in mammalian cells 
(Wendler et al. 2009). Nevertheless, we surprisingly found that ethyl pyruvate effectively 
inhibited proliferation of the trypanosomes. The absence of an antiproliferative effect of L-
ethyl lactate suggests that the reduced form is either not taken up by the cells or is not 
converted to ethyl pyruvate because these cells are deprived of lactate dehydrogenase.  
 
We found total inhibition of trypanosomes at 5 mM ethyl pyruvate within 3 hrs. This effect 
was irreversible as no recovery of the cells was achieved. Although this concentration of ethyl 
pyruvate is slightly above the Ki-value of PK for the drug (ethyl pyruvate), it inturn seemed to 
be sufficient to initiate a progressive loss of cellular ATP. 
 
Development of drug resistance in microbes and protozoa is a big challenge in therapeutic 
medicine (Jimenez 2014). Thus, the lack of drug resistance development we observed 
within 30 days of cell growth observation is a very encouraging result. Hence it can be 
suggested that the lack of drug resistance observed could arise from attacking more than 
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one target in trypanosomes since it is also known that ethyl pyruvate inhibits glyoxalase II  
in mammalian as well as yeast cells (Hollenbach et al. 2008). This enzyme is present in T. 
brucei cells but with yet undefined functions (Irsch and Krauth-Siegel 2004). Besides, it 
might also be because 30 days of exposure is short relative to the natural evolutionary 
pressure. However, we also know that the laboratory adapted T. brucei cells are capable of 
proliferating faster and the possibility of acquiring resistance against the drug in shorter 
period of expsure might also be higher. 
 
Ethyl pyruvate seems to have many targets in the cells. For instance, interference with the 
NF-kB pathway was assumed to explain its anti-inflammatory effect in mammalian cells 
(Park et al. 2011). Our recent finding that ethyl pyruvate inhibits both enzymes of the 
glyoxalase system could explain its strong inhibitory action on tumor cells given the 
decreased D-lactate production in ethyl pyruvate treated tumor cells. From our results we 
know that a wide range of tumor cells were sensitive to ethyl pyruvate but no effect could 
be seen to primary human hepatocytes (Baunacke et al. 2014). This indicates that ethyl 
pyruvate possesses a selective activity against those cells endowed with a high glycolytic 
rate. Furthermore, the potency of ethyl pyruvate is even increased when cells are 
metabolically activated by growth stimulators such as nutrients or growth factors 
(Baunacke et al. 2014). Thus, it was not a surprise that ethyl pyruvate kills trypanosomes so 
effectively because they solely rely on glucose and are highly proliferative. When we 
looked for glyoxalase I enzyme activity in whole cell extracts of trypanosomes we could 
not find any. Although this organism is said to possess a functional glyoxalase II no 
apparent GLO1 gene could be identified so far (Greig et al. 2009). Thus, T. brucei does not 
maintain an intact glyoxalase system unlike in mammalian cells. It is assumed that 
methylglyoxal most probably is metabolized via the methylglyoxal reductase and the 
lactaldehyde dehydrogenase to L-lactate. Until recently a definitive methylglyoxal 
reductase gene is not yet identified in T. brucei. However, in the genome, although not 
functionally characterized, two putative aldo-keto-reductase genes from the same aldo-keto 
reductase superfamily as methylglyoxal reductase have been annotated (Greig et al. 2009). 
In support of these findings the level of methylglyoxal reductase activity in our study was 
insignificant in the crude cell extracts of these cells (results not shown) indicating the 
absence or non-functionality of this enzyme in T. brucei cells similar to the result of 
another study (Wyllie and Fairlamb 2011). 
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It was shown that methy pyruvate, which is structurally analoguous to ethyl pyruvate, affects 
cell proliferation by blocking the pyruvate transporter that brings the toxic accumulation of 
the endogenous pyruvate leading to cell death because of acidification. As can be seen in 
figure 6, pyruvate was applied to explore whether the high concentration of pyruvate in the 
extracellular environment might stop diffusion or efflux of the endogenous pyruvate and 
indirectly explain the ultimate impact of inhibition of pyruvate diffusion due to blockage of 
pyruvate transporters. However, application of pyruvate to the T. brucei cells had no effect 
(Fig. 6). This may indirectly explain that pyruvate transporters blockage might still not be the 
mode of action of ethyl pyruvate in T. brucei cells. 
 
Therefore, we looked for other possible targets within the glycolytic pathway. Key enzymes 
directly regulating the ATP production in T. brucei are HK 1, PFK and PK (Opperdoes and 
Michels 2001; Verlinde et al. 2001). While PFK and HK were not inhibited, competitive 
inhibition of PK (Ki= 3.0±0.29 mM) by ethyl pyruvate has been ascertained for the first time.  
 
PK converts phosphoenolpyruvate to pyruvate in the cytosol for ATP production. PK activity 
is relatively abundant in the cytosol of T. brucei and is responsible for the net ATP production 
by the cell. While most cellular ATP is consumed by hexokinase and phosphofructokinase 
which are not under regulatory control, inhibition of PK would lead to a rapid loss of cellular 
ATP. PK has a provital role in T. brucei because it is a crossroad between cytosolic and 
mitochondrial metabolism particularly in the procyclic forms. Recently, it was found that loss 
of PK is lethal to glucose-adapted cells (Coustou et al. 2003). Thus, it corroborates our results 
that PK could be another target of ethyl pyruvate. The inhibitory action of ethyl pyruvate 
might be explained by a deducible structural and spatial similarity to phosphoenolepyruvate.  
 
However, results from different authors have shown that ethyl pyruvate is cell protective due 
to its ROS-scavenging and antiinflammatory activity (Wykle et al. 1980). For that it has 
already been used in phase II clinical studies for sepsis treatment. This mode of action may 
not hold true in trypanosomes as it rather kills than giving protection. 
 
The absence of side effects of ethyl pyruvate in recent clinical studies (Fink 2007; Bennett-
Guerrero et al. 2009) is also confirmed by our ex vivo investigation showing that human red 
blood cells were not struck by ethyl pyruvate. This is quite surprising because red blood cells 
are known to rely on oxidation of glucose to lactate and possess a very active glyoxalase 
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system (Mannervik et al. 1972). The lack of damage to these cells by the generated 
methylglyoxal might be due to the absence of mitochondria since methylglyoxal was shown 
to target mitochondria for induction of cell death and their high level of glutathione (Ghosh et 
al. 2011). It is well stated that the uptake and excretion of monocarboxylates such as pyruvate 
and lactate are crucial steps in regulation of energy metabolism and acid-base balance in 
many tissues, including erythrocytes. Blockage of pyruvate transporters (monocarboxylate 
transporters (MCTs)), therefore, was found to be lethal to T. brucei cells (Sanchez 2013). In 
T. brucei, ethyl pyruvate, like methyl pyruvate, might hence block these transporters and 
affect pyruvate entrance into the mitochondria or its export out of the cells. Unlike in T. 
brucei the RBCs are known to release lactate, instead of pyruvate and the T. brucei pyruvate 
transporter permeases are not related to MCTs from mammals (Sanchez 2013). These might 
also be optional reasons why ethyl pyruvate is safe to RBCs but not to T. brucei. From our PK 
inhibition study we normally would expect that ATP depletion induces cell death resulting in 
red cell hemolysis. The absence of hemolysis might be due to neutralization of ethyl pyruvate 
by glutathione and/or degradation by unspecific esterases (Song et al. 2004). 
 
Ethyl pyruvate comparatively is a safe and fast acting agent against T. brucei. However, the 
relatively higher concentration that was required to observe its best inhibition might be 
considered as a constraint when compared with the currently registered drugs which were 
effective in nM or µM concentrations (Fig. 5 and 8). Translatioed to in vivo application, ethyl 
pyruvate has to be provided in a concentrated solution in order to get an effective level of at 
least 5 mM in an animal model or in human. Therefore, the best option might be to give it 
through infusion. Phase II clinical studies in septic patients have also used this route of 
application (Bennett-Guerrero et al. 2009). In this clinical study it was also demonstarted that 
application of ethyl pyruvate using doses as high as 450 mg/kg/dy given in five divided doses 
(each 90 mg/kg) was safe to patients (Bennett-Guerrero et al. 2009). Another possibility is to 
chemically modify the chain length of the alcohol of the ester. It was shown that prolongation 
of the side chain decreased the IC50 of ethyl pyruvate for glyoxalase I by factor 2 [Patent N
o
. 
20080300303 and 20100204161]. 
 
Anti-trypanosomal drugs like eflornithine, pentamidine and suramin have proved useful in 
some limited cases. However, these drugs are far from satisfactory because of major side 
effects, the need for parenteral mode of administration and their unaffordable price for 
African countries. Moreover, some of those drugs (suramin, pentamidine) are unable to cross 
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the blood–brain barrier (BBB) to treat late-stage cases of trypanosomiasis. In addition, the 
increasing resistance to the arsenical melarsoprol (Babokhov et al. 2013), which is the main 
drug used to treat the late stage of the disease when the brain is affected in both forms of the 
disease, has increased the need for alternative drugs.  
Very recently a new combination therapeutic drug called NECT has become registered as 
antitrypanosomal drug. It is considered to be highly effective mainly in T. b. gambiense 
patients that in T. b. rhodesiense infected individuals. It additionally is with various side 
effects in 68% of patients given the treatment and showed some resistance developing 
parasite strains against it (Alirol et al. 2013). This current progress in drug discovery, 
however, gives a good hope towards the effort in disease eradication.  
As a current solution on drug discovery of NTDs, new products development partnerships 
such as Medicines sans Frontiers and the Geneva based Drugs for Neglected Diseases 
Initiative (DNDi) have been established by various research and collaborative institutes 
including the institutes like the WHO special programme on Tropical Diseases Research 
(WHO/TDR) (Hotez 2008). This initiative considers the advantage of applying those drugs 
including eflornithine and nifurtimox, which were under clinical use or trial for other chronic 
illnesses like cancer and chagas disease, to treat HAT (Barrett and Barrett 2000; Hotez 2008).  
We, therefore, tried to share this experience similarly in ethyl pyruvate and HIV-1 protease 
inhibitors application against T. brucei. Accordingly, there is ample evidence on the anti-
leishmanial and anti-malarial effects of HIV protease inhibitors both in vitro and in clinical 
isolates ( Li et al. 1996; Frappier et al. 1998; Parikh et al. 2005; Skinner-Adams et al. 2007; 
Lek-Uthai et al. 2008; Santos et al. 2009). However, the effect of these peptidase inhibitors in 
human African trypanosomes is not yet reported. Since trypanosome and mammalian 
proteasomes differ in terms of their substrate specificity (Li et al. 1996), specific and non-
toxic proteasome inhibitors are the rationale choice for further anti-trypanosomal drug 
development (Blum et al. 2001; Andreani et al. 2012). 
Thus, in our project the question for an apparent effect of HIV-1 aspartate protease inhibitors, 
ritonavir and saquinavir, in T. brucei cells in vitro was addressed. Depending on the number 
of actively moving or viable cells, our findings showed that SQV and RTV, respectively, 
induced up to 95% and 85% cell death at 50 µM concentration. At 20 µM both drugs 
inhibited survival of more than 50% of cells after 24 hrs of incubation (Fig. 13). The same 
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result was obtained using the AlamarBlue®cell proliferation assay which indicated a dose 
dependent inhibition of proliferation (Fig. 14). This anti-proliferative effect of SQV and RTV 
might either be caused by inhibition of T. brucei proteases or might be due to activation of 
apoptosis. A study done by  Santos and colleagues (Santos et al. 2009) for instance indicated a 
concentration dependent growth inhibition of leishmania cells by HIV-1 protease inhibitors 
like lopinavir, nelfinavir, amprenavir, indinavir and saquinavir. In their findings, lopinavir and 
nelfinavir resulted a statistically significant growth inhibition at 50 µM  only from. On the 
otherhand, saquinavir only marginally diminished leishmanial proliferation when compared 
with the rest of protease inhibitors applied. This indicates T. brucei are more susceptible to 
SQV when compared with leishmanial parasites (L. amazonensis). This might be because of 
the non-specific or generally toxic effects of the drugs on parasite cells or can be because of 
the possible difference in the probable proteasome target of the drug between these two 
parasite species. However, this comparison remains questionable because most of the 
inhibition experiments in the litrature focus mainly on the cystein and metallo-proteases. And  
to date there has been no study of the aspartic peptidases in African trypanosomes (Santos et 
al. 2013). 
 
Our study further tried to identify the type of proteases expressed in T. brucei cell extracts. 
The findings showed that the cysteine proteases and the metallo-proteases were the two most 
abundantly and clearly expressed proteases. This corresponds to the study done by Vermelho 
et al. (2010) who indicated the cysteine and metallo-proteinases as the major proteases 
together comprising more than 70% of all the proteases in the African trypanosomatids. 
 
An earlier study done by (Lonsdale and Mpimbaza 1986) using fibrinogen and collagen as 
substrates in SDS-PAGE electrophoresis demonstrates proteases with Mr of 28 kDa, 42 kDa, 
60 kDa, 90 kDa and 105 kDa level in T. brucei cells when fibrinogen is used. Even though 
not well expressed as in the fibrinogen co-polymerized gels they also identified proteases at 
the 28 kDa, 31 kDa, 93 kDa and 105 kDa from the same cell extract when using collagen as a 
substrate. Therefore, our results concur with the previous findings at the ~ 29 kDa and at the 
~66 kDa protein zones. In all studies the 27/28/29 kDa Mr protease was confirmed to be a 
cystein protease which is in agreement with our findings. It should be noted that more bands 
may be expressed depending on substrate specificity of the various proteases available within 
the cells. Lonsdale and Mpimbaza (1986) also mentioned that the variation in the relative 
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amount of higher Mr bands from one preparation to another appears to be related to the 
number of steps used in the purification of trypanosomes whereby excessive handling results 
in increased amounts of lower-Mr enzyme forms with a concomitant reduction in the higher-
Mr forms. The parasite clone differences may also be another possibility for this difference. 
The author also mentioned the variation in the expression of the different protease bands 
depends on the freshness of the cell extracts loaded in the gels whereby fresh extracts express 
more bands.  
 
We found that, the HIV-1 protease inhibitors, SQV and RTV, didn‘t target the cystein (~29 
kDa Mr) and metallo-proteases (~66 kDa Mr) of T. brucei. As is confirmed by Santos et al. 
(2009) on Leishmania amazonensis, lopinavir (a drug co-administered with sub-therapeotic 
doses of RTV in HIV patients) and nelfinavir effectively inhibited the aspartic proteolytic 
hydrolysis of the HIV-1 peptidase substrate by the cells. Amprenavir, however, had no 
inhibitory effect at the highest applied concentration (10 µM). Another study done on 
Plasmodium falciparum cells to determine inhibition of activity of plasmepsin II, an acidic 
food vacuole aspartate protease enzyme that appears to play a role in the initial hydrolysis of 
haemoglobin by intraerythrocytic malaria parasites, indicated that both lopinavir and ritonavir 
inhibited its activity with IC50 of 2.7 µM and 3.1 µM, respectively (Parikh et al. 2005). These 
two findings indirectly indicated that the different HIV-1 protease inhibitors may target 
different classes or types of proteases in parasites.  
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6. Conclusion 
 
Our in vitro experimental study finally presents ethyl pyruvate as a newly emerging fast 
acting, effective and safe drug with a predefined property to easily cross the BBB that can 
predict its future applicability against both stages of the disease. It has also been revealed that 
pyruvate kinase is a new target of ethyl pyruvate which might be the cause of the observed net 
ATP depletion in T. brucei cells. Further in vivo investigations are underway to determine its 
efficacy, toxicity and metabolism in infected mice. The HIV-1 protease inhibitors, RTV and 
SQV, were also effective against T. brucei cells even though their mechanism of action is not 
defined yet. It was found that these inhibitors did not target the cysteine- and metallo-
proteases in T. brucei cells and may probably target other nondefined proteases. Since they 
are clinically approved and registered drugs the possibility of applying these drugs in HAT 
patients can be cost effective and a short cut solution. It is recommended that in vitro target 
identification and preclinical drug interaction studies should be the next steps to be 
undertaken before their clinical applications.  
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7. Supporting information 
 
7.1. List of chemicals 
Chemical/reagent Pharmaceutical Company 
Baltz basic solution Sigma-Aldrich, Taufkirchen, Germany 
ß-mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
Penicillin/streptomycin Sigma-Aldrich, Taufkirchen, Germany 
Heat inactivated fetal calf serum (FCS) Biochrom, Berlin, Germany 
50 ml sterile cell culture flasks Greiner Bio-One, Frickenhausen, Germany 
AlamarBlue® Sigma-Aldrich, Taufkirchen, Germany 
96-well multiscanner  Tecan, Crailsheim, Germany 
Ethyl pyruvate Sigma-Aldrich, Taufkirchen, Germany 
Ethyl L- lactate Sigma-Aldrich, Taufkirchen, Germany 
Pyruvate (Sodium salt) ACROS ORGANICS, New Jersey USA 
Suramin. Sigma-Aldrich, Taufkirchen, Germany 
Pentamidine-isethionate (Pentacarinat® 
300) Sanoﬁ Aventis, Gouda, Netherlands 
Neubauer hemacytometer  Marienfeld, Lauda-Königshofen, Germany 
Nunclon culture dish  Sigma-Aldrich, Taufkirchen, Germany 
Inverted phase contrast microscope  DMIRB, Leica 
Tris  Roth, Karlsruhe, Germany 
PMSF Roth, Karlsruhe, Germany 
Glycerol Merck, Darmstadt, Germany 
Tritonx100 Merck, Darmstadt, Germany 
EDTA Sigma-Aldrich, Taufkirchen, Germany 
Protease inhibitor cocktail Sigma-Aldrich, Taufkirchen, Germany 
CellTiter-Glo® ATP reagent Promega, Madison, USA 
Tris/HCl  SERVA, Heidelbeg, Germany 
MgCl2 Sigma-Aldrich, Taufkirchen, Germany 
ADP Sigma-Aldrich, Taufkirchen, Germany 
Phosphoenolpyruvate Sigma-Aldrich, Taufkirchen, Germany 
Pyruvate kinase-1 (EC 2.7.1.40)  Roche GmbH, Mannheim, Germany 
96-well white opaque plate  Greiner, Frickenhausen, Germany 
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Methylglyoxal Sigma-Aldrich, Taufkirchen, Germany 
NADPH Sigma-Aldrich, Taufkirchen, Germany 
Protein marker Carl Roth, Karlsruhe, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
Gelatin Sigma-Aldrich, Taufkirchen, Germany 
CaCl2 SERVA, Heidelberg, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Comassie brilliant blue R250  Sigma-Aldrich, Taufkirchen, Germany 
SDS  SERVA, Heidelberg, Germany 
Iodoacetamide Sigma-Aldrich, Taufkirchen, Germany 
Diethyl oxalate Fluka, Sigma Aldrich Chemie GmbH 
Butyl L-lactate Fluka, Sigma Aldrich GmbH  
Isobutyl D-lactate Fluka, Sigma Aldrich GmbH  
Benzyl (S)-(-)- lactate, Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany. 
Methyl(S)-(-)-lactate  Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany. 
Isobutyl D-lactate Fluka, Sigma Aldrich GmbH  
Benzyl (S)-(-)-lactate, Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany. 
NAD Boehringer, Mannheim, Germany 
Glucose-6-phosphate dehydrogenase Boehringer, Mannheim, Germany 
ATP Roche Diagnostics, Germany 
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Introduction 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a life-threatening 
tropical disease caused by two sub-species of the kinetoplastid protozoan parasite, 
Trypanosoma brucei: T. b. gambiense and T. b. rhodensiense. Sixty million people in 36 sub-
Sahara African countries, mainly living in poverty-stricken, remote rural areas, are at risk of 
the disease. Recently, WHO reinforced disease control programs and the number of notified 
cases since 2000 has shown to steadily decline reaching lower than 10,000 new cases after 
2009. Although 7216 cases were reported in 2012, the current estimated number of new cases 
approximate to 20,000. 
During the course of the disease, there can be two distinct clinical stages. The first or early 
stage of the disease, also known as the haemolymphatic phase, is defined by the restriction of 
the trypanosomes to the blood and lymphatic system. The second or late stage of the disease, 
also known as the neurological phase, is characterised by the presence of the parasites in the 
cerebrospinal fluid. 
 
The absence of vaccines because of the inability of patients to develop a sterilizing immunity 
after a natural infection is the main discouraging challenge in disease control activities. Hence 
drugs are the only therapeutic options for the treatment of HAT. However, the drugs currently 
in use are old (developed > 50 years ago), scarce, highly toxic, difficult to administer and 
encounter parasite resistance. They are also given depending on the stage of the disease. This 
situation, therefore, calls for more research geared towards development of promising 
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compounds to ensure new drug availability in the longer term. The identification of novel 
therapeutic targets essential for parasite development is an important first step in the 
development of new anti-trypanosomal drugs. Metabolic pathways that are absent from or 
significantly different to the analogous host pathways are logical starting points for drug 
discovery. As such, enzymes in the glycolytic pathway and their major proteases have 
become attractive targets for trypanocidal drugs. 
 
In trypanosomes, it has been observed that all the available registered antitrypanosomal drugs 
including the newly listed eflornithine in NECT combination therapy are derived from cancer 
therapeutic research. This relationship of antitrypanosomal and anticancer drugs encouraged 
us to test similar other compounds like ethylpyruvate that have anti-cancer and anti-microbial 
properties. The probable similarities among trypanosome and cancer cells can be of their fast 
proliferation characteristics and they both possess a robust methygloxal metabolism process. 
However, it is known that glyoxalase I is absent and glyoxalase II is non functional within the 
methylglyoxal metabolism process in T. brucei cells. Hence the anti-glyoxalase activity of 
ethyl pyruvate in cancer cells may not be applicable to T. brucei cells. One should, therefore, 
search for other possible mechanisms of action of ethyl pyruvate, particularly in these cells. 
For instance, pyruvate is released instead of lactate as a final product to glycolysis in T. brucei 
cells. A recent study has also confirmed the role of pyruvate transporters blockage using 
methyl pyruvate, a structural analogue of ethyl pyruvate, as a promising target in 
trypanosomes. This might as well be considered as a possible mode of action of ethyl 
pyruvate in T. brucei cells. Our first hypothesis is, therefore, ethyl pyruvate may result 
efficient inhibition of T. brucei proliferation either through blockage of the unknown enzyme 
substituting glyoxalase I within the methylgloxal metabolism process, or inhibition of 
pyruvate transporters and/or other antimicrobial activities.  
In addition to the glycolytic enzymes, the parasite-derived proteases which are a group of 
enzymes that play myriad roles in the survival of trypanosomatids are also listed among the 
important targets. Initial studies have confirmed the efficacy of protease inhibitors in 
treatment of Trypanosoma cruzi, Plasmodium falciparum and Leishmania major. The 
effectiveness of HIV protease inhibitors in treating parasitic infections may similarly be 
associated to their capacity to modulate or block the cell proteasome. The objective of our 
study is, therefore, to determine efficacy of ethyl pyruvate and HIV-1 aspartate protease 
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inhibitors, saquinavir and ritonavir, on T. brucei cells and identify their corresponding 
specific targets in vitro. 
Main findings and discussion 
 
Effect of ethyl pyruvate on T. brucei cells proliferation 
It was confirmed that ethyl pyruvate effectively inhibits cell proliferation with an IC50 of 2.03 
mM and the minimum effective concentration (MIC) that gives maximum inhibition was 5 
mM. We then analysed the time range of action of ethyl pyruvate in a time dependency test. 
Our finding indicated that ethyl pyruvate completely inhibited proliferation of trypanosomes 
at 5 mM in 3 hrs of exposure. The fast acting property of ethyl pyruvate has also been re-
confirmed in video-recording and phase contrast microscopy. In this technique the change in 
pattern of cell motility was observed. Accordingly, the cytotoxic effect started after 1 hr of 
exposure and complete inhibition of cell motility that finally led to cell death was visually 
observed after 3 hrs of incubation at 5 mM ethyl pyruvate. In the time dependency test, 
contrary to ethyl pyruvate, the standard drug, pentamidine, showed similar results only after 
48 hrs of incubation.  
 
Consequently, the sudden loss of viability of trypanosomes at short-time incubation with ethyl 
pyruvate prompted us to look into the energy budget of the cells. Our results revealed that 
ATP production was significantly hampered in a concentration dependent manner. There was 
also a clear concentration dependent reduction in ATP production from 110 nM to an extent 
below 10 nM ATP per 3x10
4
 cells at ≥5 mM ethyl pyruvate. The mechanism of ethyl 
pyruvate to hamper the glycolytic pathway, which is the sole energy-phosphate delivering 
pathway in trypanosomes, was another research question. To respond to this question, we 
tried to identify possible inhibition of those glycolytic enzymes necessary for energy 
production in these cells. Therefore, we analyzed the specific activity of hexokinase-1(HK-1) 
and phosphofructokinase (PFK) in trypanosome extracts in the absence and presence of 10 
mM ethyl pyruvate. In addition, pyruvate kinase (PK) kinetic was determined at variable 
concentrations of PEP and ethyl pyruvate in a luminescence assay. Our results demonstrated 
that ethyl pyruvate showed no significant inhibition of HK-1 and PFK enzyme activities. 
However, a competitive inhibition of PK activity with Ki= 3±0.29 mM was achieved. Hence 
besides to its anti-inflammatory and anti-glyoxalase property in mammalian cells, PK might 
also be considered as a new target to ethyl pyruvate in T. brucei as well as mammalian cells. 
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To prove cell recovery, as a proxy to determine its irreversible cytotoxicity, we incubated 
cells with variable concentrations of ethyl pyruvate for 3 hrs and let the cells to replenish in 
fresh medium without the drug for 24 hrs. The results indicated that cells exposed to low 
concentrations of the drug (≤ 2.5 mM ethyl pyruvate) recovered from the cytotoxic effect of 
ethyl pyruvate and keep proliferating. In contrast, at a concentration ≥ 5 mM the cells were 
irreversibly damaged, and they have completely lost their cellular integrity. Additionally, to 
strengthen these results, the parasites were cultured in two groups in a medium containing 
sub-lethal concentrations of ethyl pyruvate (1 mM and 2 mM) for 30 days through continuous 
passaging by changing the medium and the drug every two days. At day 31
st
, the 
trypanosomes were then subjected to increasing concentrations of ethyl pyruvate. The result 
finally confirmed a similar dose-response curve as for non-sensitized cells that indicated the 
absence of parasite drug resistance against ethyl pyruvate during the specific period of 
exposure. There was aslo a statistically significant inhibition starting 1mM concentration 
unlike in control cells. Hence these results further disclosed that the cells were more sensitive 
to lower concentrations when there is continuous-low-dose-exposure to the drug for a longer 
duration. It may therefore bring a cumulative effect of cytotoxicity and parasite resistance 
development against ethyl pyruvate might not become a threat.  
 
To examine the possible toxicity of ethyl pyruvate (1 to 15 mM) to human erythrocytes in ex 
vivo experiments, the human red blood cells were incubated together with the T. brucei cells 
for 3 hrs. Our result revealed that at 5 mM ethyl pyruvate almost all T. brucei cells were dead 
while no significant change was observed in the red blood cell count and hemolysis.  
 
Effect of HIV-1 protease inhibitors on T. brucei cells proliferation and their major 
proteases  
In our experimental trials during testing of effect of HIV-1 protease inhibitors using 
AlamarBlue® cell proliferation assay, it has been affirmed that ritonavir (RTV) and 
saquinavir (SQV) effectively inhibited proliferation in a concentration dependent manner with 
IC50 of 12.23 µM and 11.49 µM, respectively. The mechanism of action of these two drugs 
was still mandatory to investigate. Inorder to determine the target of these two HIV-1 protease 
inhibitors we first had to identify the major proteases in these cells using zymography. Gelatin 
was employed as a substrate co-polymerized within the polyacrylamide gels. Accordingly, we 
have identified two major proteases with molecular masses of ~66 kDa and ~29 kDa that can 
clearly be seen as white bands in control gels.  
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To identify the specific classes of these preoteases we applied protease inhibitors for the 
cysteine-, serine- and metallo-proteases. Our results finally revealed that the ~66 kDa protein 
was a metallo-protease and the ~29 kDa was a cysteine protease. PMSF had partially inhibited 
the cysteine protease further revealing that the ~29 kDa protease is a papain-like cysteine 
protease. The metallo- and papain like cysteine-proteases were, therefore, the two major 
proteases identified in T. brucei cell lines which corresponds to a report done by others 
indicating that they covered more than 70% of the proteases in these cells. 
 
However, we found that, the HIV-1 protease inhibitors, SQV and RTV, didn‘t target the 
cystein (~29 kDa Mr) and metallo-proteases (~66 kDa Mr) of T. brucei. This finding tells us 
that there may also be other classes of proteases which are critical for survival in these cells. 
For instance, different studies had shown that both nelfinavir and lopinavir (a drug co-
administered with sub-therapeotic doses of ritonavir in HIV-1 patients), effectively inhibited 
the aspartic proteolytic hydrolysis of the HIV-1 peptidase substrate in Leishmania 
amazonensis. Another study also indicated both lopinavir and RTV inhibited activity of 
Plasmodium falciparum plasmepsins II, an acidic food vacuole aspartate protease enzyme that 
appears to play a role in the initial hydrolysis of haemoglobin by intraerythrocytic malaria 
parasites. These two studies suggest that the target of RTV and SQV in T. brucei can also be 
the aspartate proteases. However, we failed to identify the aspartate proteases in T. brucei 
cells by the applied technique. On the other hand, it might be possible that these proteases are 
present but in a very low concentration in T. brucei cells. This might be because zymography 
may not be efficient enough to demonstrated aspartate protease activities in T. brucei cells. 
Hence, enzyme kinetic studies or other enzyme activity inhibition assays using specific HIV-1 
protease substrates can be better options. 
 
Conclusion 
Our in vitro experimental study finally presents ethyl pyruvate as a newly emerging fast 
acting, safe and effective antitrypanosomal agent which is also known to easily cross the 
blood brain barrier (BBB) that shows its applicability against both stages of the disease. It has 
also been revealed that pyruvate kinase is a new target of ethyl pyruvate. This mode of action 
might be partially responsible for the net ATP depletion in T. brucei cells. The HIV-1 
protease inhibitors, RTV and SQV, were also effective against T. brucei cells eventhough 
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their mechanism of action is not yet defined. However, it was suggested that they did not 
target the cysteine- and metallo-proteases in T. brucei cells and may probably target other 
proteases. Since they are clinically approved and registered drugs the possibility of applying 
these drugs in HAT patients can be cost effective and a short cut solution. It is recommended 
that in vitro target identification and preclinical drug interaction experiments should be the 
next steps to be undertaken before their clinical applications.  
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